

*Translation
For reference only*



Stock Code: 6576

Foresee Pharmaceuticals Co., Ltd.

2026 Annual Shareholders' Meeting Meeting Handbook

(Translation)

Method of Convening the Meeting: Physical Meeting

Meeting Time: 9:30 AM, Thursday, May 21, 2026

Meeting Venue: 2F, No. 19-10, Sanchong Rd., Nangang Dist.,
Taipei City 115, Taiwan (R.O.C.)

(International Conference Center, 2F, Building A, Nangang Software Park)

Table of Contents

I.	Meeting Agenda	1
	Report Items	2
	Ratification Items	4
	Discussion Items	6
	Ad Hoc Motions	12
II.	Attachments	
	1. 2025 Business Report	13
	2. 2025 Audit Committee’s Review Report	19
	3. Execution Status of the 2025 Sound Operation Plan.....	21
	4. 2025 Private Placement Status and Utilization Report.....	24
	5. Status of the First Domestic Secured Convertible Bond Issuance	28
	6. 2025 Directors’ Compensation	31
	7. Independent Certified Public Accountant Report and 2025 Financial Statements.....	33
	8. Concurrent Position Newly Held by Director	54
	9. Relevant Information on the Issuance of Common Shares Through Cash Capital Increase for Sponsoring Global Depository Receipt Issuance and/or Conducting a Cash Capital Increase via Book-Building or Auction Methods	56
III.	Appendices	
	1. Articles of Incorporation.....	59
	2. Rules and Procedures of Shareholders’ Meeting.....	69
	3. Shareholdings of All Directors	77

I. Meeting Agenda

Foresee Pharmaceuticals Co., Ltd. Meeting Agenda for the 2026 Annual Shareholders' Meeting

Method of Convening the Meeting: Physical Meeting

Meeting Time: 9:30 AM, Thursday, May 21, 2026

Meeting Venue: 2F, No. 19-10, Sanchong Rd., Nangang Dist., Taipei City
115, Taiwan (R.O.C.)

(International Conference Center, 2F, Building A, Nangang
Software Park)

1. Call the Meeting to Order
2. Chairperson's Remarks
3. Report Items
 - (1) 2025 Business Report
 - (2) 2025 Audit Committee's Review Report
 - (3) Report on the Execution Status of the 2025 Sound Operation Plan
 - (4) Report on the 2025 Private Placement Status
 - (5) Report on Matters Relating to the Issuance of the 1st Domestic Secured Convertible Bonds
 - (6) 2025 Directors' Compensation Report
4. Ratification Items
 - (1) Ratification of 2025 Financial Statements and Business Report
 - (2) Ratification of the Proposal for Compensation of 2025 Deficit
5. Discussion Items
 - (1) Proposal to Release Directors from Non-competition Restrictions
 - (2) Proposal for the Issuance of Common Shares Through a Cash Capital Increase to Sponsor Global Depositary Receipts and/or to Conduct the Issuance of Common Shares via Book-Building, Auction Methods, and/or Private Placement
6. Ad Hoc Motions
7. Adjournment

Report Items

Item 1

2025 Business Report

Description:

For the 2025 Business Report, please refer to Attachment 1 (Pages 13 to 18).

Item 2

2025 Audit Committee's Review Report

Description:

For the 2025 Audit Committee's Review Report, please refer to Attachment 2 (Pages 19 to 20).

Item 3

Report on the Execution Status of the 2025 Sound Operation Plan

Description:

- (1) As of the end of 2025, the Company's accumulated non-compensated losses totaled NTD 6,693,790,080, exceeding one-half of its paid-in capital. In accordance with Article 211 of the Company Act, this matter is hereby reported to the Annual Shareholders' Meeting.
- (2) For the Execution Status of the 2025 Sound Operation Plan, please refer to Attachment 3 (Pages 21 to 23).

Item 4

Report on the 2025 Private Placement Status

Description:

- (1) Pursuant to the resolution of the Annual General Meeting of Shareholders held on May 29, 2025, the Board of Directors was authorized to issue up to 25,000,000 common shares through one or a combination of the following methods: cash capital increase for the issuance of common shares to sponsor Global Depositary Receipts, and/or cash capital increase via book-building or auction methods, and/or private placement of common shares. This issuance may be conducted in a single or multiple tranches within

one year from the date of the shareholders' resolution.

- (2) On September 17, 2025, the Board of Directors resolved to proceed with the first private placement of 2,500,000 common shares for the year 2025. For the 2025 Private Placement Status and Utilization Report, please refer to Attachment 4 (Pages 24 to 27).
- (3) In accordance with Article 43-6 of the Securities and Exchange Act, the authorization period for the private placement of securities will expire on May 28, 2026. If any unissued portion of the authorized amount is not successfully placed before the expiry date, the Company will not continue with the placement of such remaining portion.

Item 5

Report on Matters Relating to the Issuance of the 1st Domestic Secured Convertible Bonds

Description:

- (1) To replenish working capital and repay bank loans, the Company issued the 1st domestic secured convertible bonds (Symbol: 65761).
- (2) For the status of the issuance of the first domestic secured convertible bonds, please refer to Attachment 5 (pages 28 to 30).

Item 6

2025 Directors' Compensation Report

Description:

The Company's policies, systems, standards, and structures for the payment of remuneration to Directors; descriptions based on factors such as responsibilities, risks, and time commitment; the amount of remuneration paid; and the correlation with performance evaluation results.

- (1) In accordance with Article 25 of the Company's Articles of Incorporation, the Board of Directors is authorized to determine the compensation of all Directors based on their level of participation in the Company's operations, the value of their contributions, and in reference to industry standards.
- (2) Article 28 of the Company's Articles of Incorporation also stipulates that if there is profit for the year, any remaining balance

after offsetting accumulated losses shall be allocated as remuneration to Directors at a rate not exceeding 2%.

- (3) All Directors receive compensation for their business execution, which includes a transportation subsidy based on their attendance. Additionally, as all Independent Directors serve as members of the Audit Committee and Compensation Committee, and therefore undertake greater responsibilities, they also receive a fixed monthly salary as compensation. This is deemed reasonable compensation provided by the Company.
- (4) For the 2025 Directors' Compensation, please refer to Attachment 6 (Pages 31 to 32).

Ratification Items

Item 1 (Proposed by the Board of Directors):

Ratification of 2025 Financial Statements and Business Report

Description:

- (1) The Company's 2025 individual and consolidated Financial Statements and Business Report were approved by the Audit Committee and the Board of Directors. The Financial Statements have been audited by independent certified public accountants Lori Tsai and Yu-Fun Yen of PricewaterhouseCoopers Taiwan, and an auditors' report with an unqualified opinion has been issued.
- (2) The 2025 Business Report is attached as Attachment 1 (Pages 13 to 18). The Independent Certified Public Accountants' Report and other Financial Statements are attached as Attachment 7 (Pages 33 to 53)
- (3) The above is hereby submitted for ratification.

Resolution:

Item 2 (Proposed by the Board of Directors):

Ratification of the Proposal for Compensation of 2025 Deficit

Description:

- (1) Please refer to the following 2025 Deficit Compensation

Statement:

Foresee Pharmaceuticals Co., Ltd.
2025 Deficit Compensation Statement

(In NTD)

Items	Amount
Unappropriated accumulated deficit of prior years	\$(5,810,639,876)
Add: 2025 net loss	(883,150,204)
Deficit yet to be compensated	\$ (6,693,790,080)

Chairman: Ben Chien; CEO: Ben Chien; Head of Accounting: Ruby Chen

(2) The above is hereby submitted for ratification.

Resolution:

Discussion Items

Item 1 (Proposed by the Board of Directors):

Proposal to Lift the Non-Compete Restriction on Director

Description:

- (1) Pursuant to Article 209 of the Company Act, a Director who conducts any activity for himself/herself or on behalf of another person that falls within the scope of the Company's business shall explain the essential contents of such activity to the shareholders' meeting and secure its approval.
- (2) On the premise that there is no harm to the Company's interests, it is proposed to the shareholders' meeting to approve the release of the non-compete restriction on the Company's Directors who invest in or operate other companies with the same or similar business scope as the Company and serve as directors or managers thereof.
- (3) For details regarding the concurrent position newly held by the Director in another company, please refer to Attachment 8 (pages 54 to 55).
- (4) The above proposal is hereby submitted for resolution.

Resolution:

Item 2 (Proposed by the Board of Directors):

Proposal for the Issuance of Common Shares Through a Cash Capital Increase to Sponsor Global Depository Receipts and/or to Conduct the Issuance of Common Shares via Book-Building, Auction Methods, and/or Private Placement

Description:

- (1) To support business growth, meet working capital requirements, and enhance the flexibility and timing of fundraising, the Company plans to issue up to 35,000,000 common shares, either in one or a combination of the following financing instruments, as deemed appropriate based on market conditions, the Company's financial position, and in compliance with applicable regulations.
- (2) The Relevant Information on the Issuance of Common Shares Through Cash Capital Increase for Sponsoring Global Depository Receipt Issuance and/or Conducting a Cash Capital Increase via Book-Building or Auction Methods are provided in Attachment 9 (Pages 56 to 58).
- (3) The explanations regarding the issuance of common shares for cash through private placement are as follows:
 - A. The following matters regarding the Private Placement are provided in accordance with Article 43-6 of the Securities and Exchange Act:
 - (A) Basis and reasonableness of the private placement pricing:
 - a. The pricing of this private placement of common shares shall be no less than 80% of the reference price. The reference price shall be the higher of the following two calculations:
 - (I) The simple arithmetic average of the closing prices of the common shares for 1, 3, or 5 consecutive business days prior to the pricing date, adjusted for stock dividends, ex-rights and ex-dividends, and further adjusted for capital reduction.
 - (II) The simple arithmetic average of the closing prices of the common shares for the 30 consecutive business days prior to the pricing

date, adjusted for stock dividends, ex-rights and ex-dividends, and further adjusted for capital reduction.

- b. The subscription price for the common shares in this private placement shall be no less than 80% of the reference price. The actual pricing date and the final private placement price will be determined within the range approved by the shareholders' meeting. The Board of Directors is authorized to set the price based on the specific investors and market conditions at the time.
- c. The determination of the subscription price for the common shares in the private placement is based on the company's stock price and complies with the relevant regulations regarding the issuance of private placement securities by publicly listed companies, and is therefore reasonable.

(B) Method of selection of specific investors:

The target investors for this private placement are limited to specific persons who meet the requirements set forth in Article 43-6 of the Securities and Exchange Act and the relevant regulations, including Financial Supervisory Commission Order No. 1120383220 dated September 12, 2023.

- a. The places have not yet been determined. However, to enhance the feasibility of this private placement, the company intends to approach insiders or related parties, as they have a better understanding of the company's operations.

The list of insiders or related parties:

No.	Name of Insider	Title
1	Foresee Pharmaceuticals, Inc. Representative : Ben Chien	Chairman & CEO
2	Jennifer Yen	Spouse of Chairman
3	Foresee Pharmaceuticals, Inc. Representative : Yisheng Lee	Director, and Chief Medical Officer
4	Foresee Pharmaceuticals, Inc. Representative : Vincent Yen	Director
5	George Lee	Director

No.	Name of Insider	Title
6	Jeff Wang	Director
7	Frank Lee	Independent Director
8	Fu-Shiow Yin	Independent Director
9	Hank Lai	Independent Director
10	Ben Liu	Independent Director
11	Yuhua Li	Chief Technology Officer
12	Wenjin Yang	Chief Scientific Officer
13	Bassem Elmankabadi	Senior Vice President of Clinical Development
14	Mathieu Boudreau	Chief Business Officer & Chief Operating Officer
15	Max Chan	Chief Financial Officer
16	John Sheehan	Vice President, Pharmaceuticals and Manufacturing
17	Bill Miller	Vice President of Regulatory Affairs
18	Ruby Chen	Accounting Manager
19	Stephanie Tsai	Assistant Manager of Investor Relations
20	Jack Zheng	Auditor
21	QPS Taiwan	Related Party

Matters that should be disclosed if the placees are legal persons:

Legal Person Placee	The Shareholders with Top 10 Shareholding Percentage	Relationship with the Company
Foresee Pharmaceuticals, Inc.	Liao-Wei Yan (69.23%)	A first-degree blood relative of the representative of the Company's corporate director.
	Ben Chien (12.52%)	Chairman & CEO
	Benjamin Mingta Chien, Trustee of the Chien and Yen Family Trust (0.57%)	The Chairman's family trust of the Company
	Jennifer Chungfan Yen, Trustee of the Chien and Yen Family Trust (14.82%)	The Chairman's family trust of the Company
	Jennifer Chungfan Yen, as Trustee of the Non-GST Article III Lifetime Trust under the Chien Family Irrevocable Trust (2.86%)	The Chairman's family trust of the Company
QPS Taiwan	QPS Holding, LLC (93.67%)	Related Party
	Genovate Biotechnology Co.,	None

Legal Person Placee	The Shareholders with Top 10 Shareholding Percentage	Relationship with the Company
	Ltd. (6.33%)	

- b. If any of the placees are strategic investors, the method of selection, purpose, necessity, and expected benefits are as follows:

To address market competition and support the Company's long-term business development, the introduction of funds from financial and strategic investors is expected not only to strengthen the Company's financial structure and maintain its market competitiveness, but also to enhance its technological capabilities or optimize its production and sales framework with the assistance of such investors. These contributions are anticipated to significantly promote the Company's future operational performance and profitability. Therefore, it is necessary for the placees in this private placement to be financial or strategic investors. It is proposed that the shareholders authorize the Board of Directors to have full authority in handling all matters related to the engagement of such specific persons.

- (C) The necessity of conducting private placement:

Considering the efficiency and simplicity of private placements, and the regulatory restriction that privately placed securities may not be freely transferred within three years, a long-term relationship between the Company and the placees can be further ensured. In addition, by authorizing the Board of Directors to conduct the private placement based on the Company's actual operational needs, the flexibility and responsiveness of the Company's capital-raising efforts can be significantly enhanced.

- (D) With respect to the common shares issued in this private placement, the Board of Directors shall be authorized to apply, in accordance with relevant laws and regulations, for supplementary procedures for public issuance and for TWSE/TPEX listings after a period of three years from the date of delivery of the privately placed securities.

- B. Purpose of the capital raised and expected benefits: The funds raised in this round are expected to be used to replenish working capital, strengthen the financial structure, and meet the Company's long-term development needs. Depending on market conditions and the status of seeking specific places, the Company will conduct the placement in a single tranche within one year from the date of the shareholders' resolution. The private placement is expected to enhance the Company's competitiveness, improve operating efficiency, and strengthen the financial structure, which will have a positive impact on shareholders' equity.
- C. The common shares to be issued through this cash capital increase—whether to sponsor GDRs, through book-building, auction methods, or via private placement—will all be issued or delivered in dematerialized form. Except for the privately placed securities, which are subject to a three-year transfer restriction from the date of delivery in accordance with Article 43-8 of the Securities and Exchange Act, the rights and obligations of the privately placed common shares will be identical to those of the existing common shares.
- D. Reasonableness of and rationale for issuing common shares at a price below par value for the purpose of sponsoring GDRs, conducting a cash capital increase via book-building or auction methods, and/or private placement: In the event that the issue price per share is set below par value in response to market fluctuations, and alternative fundraising methods are not adopted, the main consideration lies in maintaining the Company's operational stability and financial soundness. Compared with pure debt instruments, equity-related financing tools are more suitable in this context. Raising funds through equity offerings such as the issuance of common shares for sponsoring GDRs or through private placement would not incur interest expenses, thereby reducing financial risk, while immediately improving the Company's financial structure and increasing its financial flexibility. Therefore, the use of equity-related fundraising instruments in this case is considered reasonable. Should the issue price be below par value, it may result in a reduction of the Company's capital surplus or retained earnings on the books; such effects will be addressed

and remedied in due course depending on the Company's actual operating performance. The issuance price will be determined in accordance with applicable regulations. Once the capital increase takes effect, the Company's financial structure is expected to be significantly improved, which will be beneficial to the Company's long-term development and should not adversely affect shareholders' equity.

- E. Following the approval of the proposal for the issuance of common shares through a cash capital increase—whether to sponsor GDRs, through book-building or auction methods, or via private placement—by the shareholders' meeting, it is proposed that the shareholders authorize the Board of Directors to determine, adjust, and fully handle all matters related to this capital raising based on the Company's actual needs, market conditions, and relevant laws and regulations. Such matters include the issuance or private placement terms, the capital utilization plan, the purpose of funds, the expected schedule, the anticipated benefits, and other related issues. In the event that changes or adjustments are required due to amendments to laws or regulations, instructions from competent authorities, operational evaluations, or other objective changes in market conditions, it is further proposed that the shareholders authorize the Board of Directors to fully handle such matters at its sole discretion.
- F. To implement the capital raising plan, it is proposed that the Chairman or a person designated by the Chairman be authorized to represent the Company in handling all matters relating to the issuance of common shares through a cash capital increase—whether for the purpose of sponsoring GDRs, through book-building or auction methods, or via private placement—and to sign all relevant agreements and documents on behalf of the Company.
- G. Any matters not addressed herein shall be fully handled by the Board of Directors in accordance with applicable laws and regulations as authorized by the shareholders' meeting.

(4) The above proposal is hereby submitted for resolution.

Resolution:

Ad Hoc Motions

Adjournment

Attachment 1

2025 Business Report

2025 Business Report

Dear Shareholders:

It is my pleasure to present to you Foresee's 2025 operation results and 2026 business plan.

I. Operating Performance in 2025

(I) Result of Implementation of 2025 Business Plan

Foresee reported a 2025 operating revenue of NT\$ 431,274 thousand, representing a year-over-year growth of approximately 3% and setting a new record high. This growth was primarily driven by the recognition of royalty revenues and commercial product sales of the CAMCEVI 6-month formulation (FP-001) for advanced prostate cancer following its U.S. launch, milestone payments from the U.S. FDA approval of the CAMCEVI ETM 3-month formulation, and milestone payments triggered by the China NMPA's acceptance of the CAMCEVI 6-month NDA for substantive review.

The CAMCEVI 6-month formulation was first launched in the U.S. in April 2022. With end-market sales volume in the U.S. continuously reaching new highs, it has steadily generated a sustained and growing cash flow for Foresee. Regarding international market expansion outside the U.S., Foresee made its first shipment to its licensing partner Accord Healthcare's warehouse in Germany in December 2024, followed by successive launches across several EU countries. In China, Foresee's licensing partner, Changchun GenSci, submitted the NDA for the CAMCEVI 6-month formulation to the NMPA in February 2025, which has now entered the substantive review phase.

For the CAMCEVI 3-month formulation, which targets an even larger market size, Foresee obtained U.S. FDA approval in August 2025, with a U.S. launch anticipated in the fourth quarter of 2026. Furthermore, the EU marketing authorization application for the CAMCEVI 3-month formulation submitted by our licensing partner Accord Healthcare has received a positive opinion recommending approval from the EMA's Committee for Medicinal Products for Human Use (CHMP). As both the 6-month and 3-month formulations of CAMCEVI progressively enter major global markets, the supply stability and economies of scale brought by capacity expansion will gradually translate into mid-to-long-term revenue growth momentum for Foresee.

The second indication for the CAMCEVI® 6-month formulation is targeted at treating Central Precocious Puberty (CPP). The multinational, multicenter Phase 3 clinical trial successfully announced positive topline results in December 2025, with an NDA submission to the U.S. FDA planned for the third quarter of 2026. Additionally, licensing partner Changchun GenSci has completed a Phase 3 clinical trial in China for the CAMCEVI 6-month formulation indicated for premenopausal breast cancer, and plans to submit a marketing authorization application to the China NMPA this year.

The maturity and commercial value of Foresee's proprietary Stabilized Injectable Formulation - Long-Acting Injectable (SIF-LAI) technology have been progressively validated following the successful out-licensing of CAMCEVI in major global markets, the securing of regulatory approvals for the 6-month formulation in the U.S., Canada, EU,

Taiwan, Israel, and the UK, and its successful commercial launches across multiple countries. Moving forward, whether it involves expanding indications for the 6-month formulation, applying for marketing authorizations for the 3-month formulation, or developing new drugs based on the SIF-LAI technology, these efforts will proceed with significantly enhanced efficiency. Foresee's mid-to-long-term revenue is expected to compound exponentially, showcasing highly promising growth potential.

Regarding the R&D progress of New Chemical Entities (NCEs), the Phase 2 Proof-of-Concept study for the MMP-12 inhibitor FP-025 (aderamastat) in allergic asthma conducted in the Netherlands has been completed with positive results. Future development will focus on rare diseases associated with immune-fibrosis. The follow-on MMP-12 inhibitor FP-020 (linvemastat) completed a Phase 1 clinical trial in healthy volunteers in Australia in 2024 and mid-term animal toxicology studies in 2025. An Investigational New Drug (IND) application for a Phase 2 clinical trial targeting asthma was submitted to the U.S. FDA in the first quarter of 2026. Licensing discussions with international pharmaceutical companies have commenced as human clinical trials progressively initiate.

However, as Foresee's MMP-12 inhibitors are first-in-class compounds and MMP-12 is not yet a fully validated target, international pharmaceutical companies tend to require comprehensive safety and efficacy data from a substantial number of patients during licensing evaluations to mitigate risk, especially when compared to "me-too" or "me-better" compounds with validated targets. Despite nearly two years of effort, Foresee has been unable to out-license the MMP-12 inhibitors to international pharma at this stage. The substantial expenditure required for NCE development and the current challenges in out-licensing would increase Foresee's operational risks and the uncertainty of the timeline to reach profitability. To achieve profitability as early as possible, since 2025, Foresee has successively terminated or suspended R&D projects that lack short-term benefits, including the ALDH2 activator FP-045 for Fanconi anemia and FP-014 (triptorelin) for advanced prostate cancer. The organizational structure has also been correspondingly optimized and streamlined.

To forge a new growth path for Foresee's NCE pipeline, following approval at the extraordinary shareholders' meeting in December 2025, Foresee's wholly-owned U.S. subsidiary, Foresee Pharmaceuticals USA Inc., signed a global exclusive licensing agreement in January 2026 with Primevera Therapeutics, LLC (a new company established by Foresee's related party, QPS) for the MMP-12 inhibitor series compounds. The licensed programs cover FP-025, FP-020, and third-generation compounds still in the drug discovery phase. Upon signing, Foresee's U.S. subsidiary received an upfront payment of US\$ 10 million. The agreement also includes potential regulatory milestone payments up to US\$ 214.5 million, potential sales milestone payments up to US\$ 360 million (totaling up to US\$ 584.5 million in combined upfront and milestone payments), and single-digit percentage royalties on sales. Furthermore, Foresee will hold a 19% equity stake in Primevera. Under the premise of not having significant influence over Primevera, Foresee will not be required to recognize Primevera's losses proportionately. This licensing agreement marks an important milestone in Foresee's operational strategy, enabling the company to optimize resource allocation, progressively focus on the development of its SIF-LAI pipeline, and accelerate its path to profitability.

In order to make company's information more accessible to shareholders and the general public, we have established our corporate website, in both English and Chinese, for regular updates of company's operations and product development progress. Please visit our websites at www.foreseepharma.com for latest update of the Company.

(II) Finance and Profitability Analysis

Item		Fiscal Year	
		2024	2025
Financial Structure (%)	Debt to Asset Ratio	25.94	29.06
	Ratio of Long-Term Capital to Property, Plant and Equipment	857.46	593.81
Solvency (%)	Current Ratio	462.23	344.29
	Quick Ratio	378.52	262.98
Profitability	Net Profit Margin (%)	-258.20	204.78
	Earnings per Share (NT\$)	-7.87	-5.7

(III) Research and Development Status

1. R&D expenditures for 2025 (in NT\$ K)

Item		Fiscal Year	
		2025	
Revenue (A)		NT\$431,274 K	
Research and Development Expenses (B)		NT\$975,130 K	
Total Number of Employees (C)		48	
Total Number of R&D Personnel (D)		26	
Percentage of R&D Personnel in the Total Workforce (D/C)		54.2%	

2. R&D Results for 2025

- A. CAMCEVI 42mg (leuprolide injectable emulsion): The Chinese registration clinical trial for the treatment of advanced prostate cancer announced the achievement of its primary efficacy endpoint in February 2024. The Chinese licensing partner, Changchun GenSci, submitted the New Drug Application (NDA) for the CAMCEVI 6-month formulation to the National Medical Products Administration (NMPA) in February 2025, which has now entered the substantive review phase.
- B. CAMCEVI ETM (3-month formulation): In August 2025, the formulation received marketing approval from the U.S. Food and Drug Administration (FDA).
- C. CAMCEVI 42 mg (6-month formulation) for Central Precocious Puberty (CPP): The Phase 3 clinical trial announced positive topline results in December 2025, demonstrating high statistical significance (P-value = 0.0005). In February 2026, it received its fourth consecutive positive safety feedback from the Data and Safety Monitoring Board (DSMB), recommending the continuation of the trial as originally planned. (The Caspian trial design includes regular evaluations and safety monitoring for up to 12 months following the first injection).

- D. ALDH2 Activator FP-045: In October 2024, the formulation received approval from the Taiwan Food and Drug Administration (TFDA) to conduct a Phase 2 clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD). The First Patient Dosed milestone was achieved in May 2025.

(IV) Budget Implementation

The Company did not disclose the financial forecast for 2025. The overall budget execution was consistent with the internal objectives.

II. Summary of Business Plan for 2026

Foresee is a R&D-driven new drug development company.

(I) Main R&D Goals

1. Complete the Phase 3 clinical trial report for FP-001 42 mg (CAMCEVI 42 mg) in central precocious puberty (CPP) and submit a New Drug Application (NDA) to the U.S. FDA.
2. Continue the development of new pipeline projects utilizing the SIF platform technology.
3. Execute the Phase 2 clinical trial of FP-045 (mirivadelgat) in pulmonary hypertension associated with interstitial lung disease (PH-ILD).

(II) Main Business and Product Goals

1. Prepare for the commercial launch for CAMCEVI 21 mg (3-month LAI formulation) in the U.S. and the EU.
2. Assist the Chinese licensing partner, Changchun GenSci, with the NDA review process for the leuprolide injectable emulsion (CAMCEVI 42 mg, 6-month formulation) in China.
3. Secure international out-licensing deals for the SIF technology platform and/or the ALDH2 activator.
4. Expand manufacturing capacity and build supply chain resilience, including process optimization and phased equipment upgrades at the Fareva manufacturing facility in France.

III. Future Corporate Development Strategy

Foresee's SIF drug delivery platform aims to fulfill the unmet needs by improving efficacy, mitigating side effects, increasing convenience, or expanding clinical applications of existing drugs.

The novel formulation drug CAMCEVI 42 mg (6-month formulation) for the treatment of advanced prostate cancer has obtained marketing approvals in the U.S., Canada, the EU, Taiwan, Israel, and the UK, with NDA applications for other major global markets currently under review or in preparation. CAMCEVI 21 mg (3-month formulation) obtained U.S. FDA approval in August 2025. In March 2026, Foresee was notified by its EU licensing partner that it had received a positive opinion from the CHMP recommending marketing authorization. Furthermore, the Phase 3 clinical trial of CAMCEVI 42 mg (6-month formulation) for central precocious puberty (CPP) and its NDA submission for premenopausal breast cancer in China are actively advancing. Other drug candidates developed utilizing the SIF platform technology are also slated to systematically advance into clinical trials in the future.

IV. The Impacts of the External Competition, Regulatory, and Macroeconomic Environments

The research and development process of new drugs is a complex and time-consuming process, which requires substantial funds and resources. Shortening the development timeline and accelerating product launch forms a key competitive factor. Foresee's pharmaceutical development model consists of a highly efficient drug selection process, and a proof of concept study prior to entering the clinical trial, and negotiation with FDA to propose reasonable and convenient clinical and regulatory pathways. This reduces the time and resources required for the selection of candidate drugs as well as the development risks. At the same time, we seek through long-term partnerships with upstream and downstream partners to maximize the value of R&D results.

Foresee's mission is to provide patients with more medical options in comfort, compliance, convenience, and cure, and to improve patients' quality of life. Foresee will continue to strive for continuous growth in the future. On behalf of the management team, I would like to offer our sincere gratitude to your faith and continuous support.

Chairman : Ben Chien CEO : Ben Chien Head of Accounting : Ruby Chen

Attachment 2

2025 Audit Committee's Review Report

Foresee Pharmaceuticals Co., Ltd.
Audit Committee's Review Report

The Board of Directors has prepared the Company's 2025 Business Report, Financial Statements, and Deficit Compensation, among which the Financial Statements have been audited by Lori Tsai and Yu-Fun Yen, CPAs of PwC Taiwan, and an audit report has been issued. The above Business Report, Financial Statements, and Deficit Compensation have been reviewed and determined to be correct and accurate by the Audit Committee. It is hereby submitted this Report is prepared in accordance with Article 14-4 of the Securities and Exchange Act and Article 219 of the Company Act.

Please kindly note accordingly.

To

The Company's Annual Shareholders' Meeting of 2026.

Foresee Pharmaceuticals Co., Ltd.

The convener of Audit Committee : Hank Lai

On the date of March 13, 2026

Attachment 3

Execution Status of the 2025 Sound Operation Plan

Foresee Pharmaceuticals Co., Ltd.

Execution Status of the 2025 Sound Operation Plan

Unit: NT\$'000

Account \ Year	2025 Audited	2025 Estimated	Difference	Difference%
Operating Revenue	431,274	442,770	(11,496)	-2.60%
Operating Costs	137,057	149,117	(12,060)	-8.09%
Gross Profit	294,217	293,653	564	0.19%
Operating Expenses				
- Selling and Administrative	181,403	181,798	(395)	-0.22%
- R&D Expenses	975,130	1,007,374	(32,244)	-3.20%
Total Operating Expenses	1,156,533	1,189,172	(32,639)	
Operating Loss	(862,316)	(895,519)	33,203	-3.71%
Loss Before Tax	(858,203)	(895,535)	37,332	-4.17%
Income Tax Expenses	24,948	27,010	(2,062)	-7.63%
Net Loss After Tax	(883,151)	(922,545)	39,394	-4.27%

Analysis of Operating Revenue, Costs, and Expenses

Operating revenue for FY2025 was NT\$431,274 thousand, comprising NT\$46,103 thousand in deferred revenue from CAMCEVI 3-month formulation, NT\$133,032 thousand in milestone revenue from CAMCEVI 3-month formulation, NT\$114,931 thousand in product sales revenue, NT\$3,928 thousand in service revenue, NT\$11,823 thousand in other revenue, and NT\$121,457 thousand in sales royalty income. The variance in operating revenue was primarily attributable to a decrease of NT\$19,083 thousand in product sales revenue compared to the forecast, mainly due to reduced production output resulting from quality inspection and testing at the Contract Development and Manufacturing Organization site in France, which led to a decline in commercial supply.

Cost of revenue amounted to NT\$137,057 thousand, mainly consisting of cost of goods sold of NT\$105,156 thousand, write-offs of short-dated injectable products of NT\$13,210 thousand, technical service costs related to FP-001 21 mg NDA filing of NT\$8,104 thousand, amortization of capitalized costs of NT\$9,734 thousand, and other costs of NT\$853 thousand. The variance in cost of revenue was primarily due to actual cost of goods sold being NT\$10,600 thousand lower than forecast, mainly resulting from reduced production output and commercial supply caused by quality inspection and testing at the Contract Development and Manufacturing Organization site in France.

Selling and administrative expenses amounted to NT\$181,403 thousand, representing a decrease of NT\$395 thousand compared to the forecast, with no material variance.

Research and development expenses totaled NT\$975,130 thousand, representing a decrease of NT\$32,244 thousand compared to the forecast. This was mainly due to delays in the PH2 clinical trial(WINDWARD study) in Taiwan for FP-045 targeting pulmonary hypertension-interstitial lung disease (PH-ILD). The originally designed clinical trial protocol included relatively stringent enrollment patient requirements. Following trial initiation, recent feedback indicated that these requirements were not fully aligned with current clinical practice, resulting in slower-than-expected patient enrollment. In response, Foresee is extending the patient enrollment period in Taiwan and evaluating adjustments to the enrollment criteria, without compromising scientific integrity or patient safety. Accordingly, the related expenses were deferred.

Foresee is supported by an internationally experienced management team with strong R&D capabilities and continues to advance its development programs, with results gradually materializing in recent years. Leveraging its SIF platform, CAMCEVI, a novel formulation for the treatment of advanced prostate cancer, has been successfully licensed across major global markets including Europe, China, and the United States. Sales of CAMCEVI in the U.S. market have continued to reach new historical highs. In the third quarter of Year 2025, Foresee obtained FDA approval for the 3-month formulation (CAMCEVI 21 mg) and has initiated pre-launch activities in the United States. Outside the U.S., Foresee has submitted a marketing authorization application for the 6-month formulation of CAMCEVI to China's NMPA, and in the first quarter of Year 2025, submitted a marketing authorization application for the 3-month formulation to the EMA. Looking ahead, Foresee expects to gradually reduce losses and move toward profitability through milestone payments and royalty income generated from these programs.

2025 Private Placement Status and Utilization Report

Item	2025 1st Private Placemen Issuance Date: November 14, 2025
Type of Privately Placed Securities	Common Shares
Date and Amount Approved by the Shareholders' Meeting	Pursuant to the resolution of the Annual General Meeting held on May 29, 2025, the Company is authorized to issue up to 25,000,000 common shares. Depending on market conditions and the Company's capital requirements, the fundraising may be conducted through one or a combination of the following methods: cash capital increase for the issuance of common shares to participate in the issuance of Global Depository Receipts, cash capital increase via book building or competitive bidding, and/or private placement of common shares for cash capital increase. The issuance(s) may be carried out in one or multiple tranches within one year from the date of the shareholders' meeting resolution.
Basis for determination of the pricing and its reasonableness	<p>1. According to the "Directions for Public Companies Conducting Private Placement of Securities," the Reference Price shall be the higher of the following two calculations: (i) the simple arithmetic average of the closing prices of the Company's common shares for either 1, 3, or 5 business days preceding the pricing date, adjusted for any stock dividends, cash dividends, and capital reductions (with reverse ex-rights adjustment); (ii) the simple arithmetic average of the closing prices of the common shares for 30 business days preceding the pricing date, similarly adjusted. The subscription price per share for the private placement shall not be lower than 80% of the aforementioned Reference Price.</p> <p>2. Based on the aforementioned pricing principles, the pricing date was set as September 17, 2025 (the date of the Board of Directors meeting). The simple arithmetic averages of the closing prices for 1, 3, and 5 business days preceding the pricing date were NT\$81.8, NT\$81.9, and NT\$82.4, respectively. The closing average price of the 1st preceding day (NT\$81.8) was selected as the first benchmark after adjusting for dividends and capital changes. Meanwhile, the 30-day simple arithmetic average closing price was NT\$80.3. Comparing these two benchmarks, the higher value of NT\$81.8 was determined as the Reference Price. The actual issue price is set at NT\$72, which represents 88.0% of the Reference Price, complying with the requirement that it shall not be lower than 80% of the Reference Price as resolved by the Annual General Meeting.</p> <p>3. The pricing of the common shares for this private placement is determined based on the average closing prices of the Company's common shares on the centralized trading market over a specific period. Therefore, the pricing method and conditions are in compliance with relevant laws and regulations and are considered reasonable.</p>
Selection of Specific Persons	The offerees of this private placement shall be limited to specific persons who meet the requirements set forth in Article 43-6 of the Securities and Exchange Act and the Financial Supervisory Commission Order No. 1120383220 dated September 12, 2023.

Item	2025 1st Private Placemen Issuance Date: November 14, 2025				
Necessary Reasons for the Private Placement:	Considering the relative efficiency and convenience of a private placement, and that the three-year restriction on the free transfer of privately placed securities will better ensure a long-term relationship between the Company and the subscribers; furthermore, authorizing the Board of Directors to conduct the private placement based on the actual operational needs of the Company will effectively enhance the flexibility and agility of the Company's fund-raising. Therefore, conducting the private placement is deemed necessary.				
Number of Shares	2,500,000 shares				
Payment Completion Date	September 22, 2025				
Delivery Date	November 14, 2025				
Subscriber Information	Subscriber	Eligibility	Shares Subscribed	Relationship with the Company	Participation in Company Operations
	QPS Taiwan	Subparagraph 3, Paragraph 1, Article 43-6 of the Securities and Exchange Act	2,500,000	A related party of the Company	Related party of the Company
Actual Subscription Price	NT\$72 per share				
Difference between Actual Subscription Price and Reference Price	The actual subscription price is NT\$72 per share, which represents 88.0% of the reference price of NT\$81.8 per share.				
Impact of the Private Placement on Shareholders' Equity	Raising funds through the private placement of common shares not only avoids interest expenses associated with debt and reduces the Company's financial risk, but also immediately improves the Company's financial structure and enhances the flexibility of its financial management. It is expected to strengthen the Company's competitiveness, improve operational efficiency, and fortify its financial structure, which will have a positive impact on shareholders' equity.				

Item	2025 1st Private Placemen Issuance Date: November 14, 2025					
Status of Private Placement Fund Utilization and Project Execution Progress	Unit: NT\$ thousands					
	Project Item		Scheduled Completion Date	Total Funds Required	Scheduled Fund Utilization Progress	Actual Fund Utilization Progress
					2026	2026
					Q1	Q1
	Enrichment of Working Capital	Clinical trial outsourcing expenses	2026 Q2	158,000	63.29%	27.87%
Others		2026 Q1	22,000	100.00%	100.00%	
As of the end of 2026 Q1, unutilized funds totaled NT\$113,973 thousand, all of which was deposited in bank demand and time deposits.						
Realization of Benefits from Private Placement	The Company raised NT\$180,000 thousand through this private placement of common shares for the enrichment of working capital. The proceeds are intended to enhance operational efficiency, strengthen the financial structure, and reserve room for the flexible utilization of funds in the future, thereby providing a positive impact on shareholders' equity.					

**Status of the First Domestic Secured Convertible
Bond Issuance**

Name	Foresee Pharmaceuticals Co., Ltd.'s 1st Domestic Secured Convertible Bonds
Date and Reference Number of Approval	Financial Supervisory Commission Letter No. 1140369448 dated January 29, 2026
Purpose of Issuance	Enrichment of working capital and repayment of bank loans
Total Issue Amount	NT\$400,000,000
Par Value	NT\$100,000
Issue Price	NT\$104.51
Issue Date	March 25, 2026
Maturity Period	3 years (March 25, 2026 – March 25, 2029)
Coupon Rate	0%
Date and Method of Principal Repayment and Interest Payment	According to Article 5 of the Issuance Regulations, the coupon rate of this bond is 0%; therefore, no interest payment date or method is required. Except for cases where bondholders convert their bonds into the Company's common shares pursuant to Article 10, exercise their put options pursuant to Article 19, the Company exercises its early redemption right pursuant to Article 18, or the Company repurchases and cancels the bonds through the over-the-counter market, the Company shall repay the bondholders the par value of the bonds held by them in a single lump-sum cash payment within ten business days after the maturity date. If the aforementioned date falls on a non-business day for the Taipei Exchange, it shall be postponed to the following business day.
Initial Conversion Price	NT\$84.30 per share
Latest Conversion Price	NT\$84.30 per share
Conversion Period	June 26, 2026 – March 25, 2029
Paying Agent and Conversion Agent	CTBC Bank Co., Ltd., Transfer Agency Department

Name	Foresee Pharmaceuticals Co., Ltd.'s 1st Domestic Secured Convertible Bonds				
Status of Fund Utilization and Project Execution	Unit: NT\$ thousands				
	Project Item	Scheduled Completion Date	Total Funds Required	Scheduled Fund Utilization Progress	Actual Fund Utilization Progress
				2026	2026
				Q1	Q1
	Enrichment of Working Capital	2026 Q4	221,024	0.00%	7.79%
Repayment of bank borrowings	2026 Q2	197,000	0.00%	100.00%	
Status of Conversion	<p>As of the end of 2026 Q1, unutilized funds totaled NT\$203,787 thousand, all of which were deposited in bank demand and time deposits without being diverted to other purposes. The Company will continue to execute the remaining funds in accordance with the capital utilization plan.</p> <p>The period from March 25, 2026, to June 25, 2026, is a three-month lock-up period following the issuance of the bonds (Conversion Lock-up Period), during which bondholders may not apply to convert the bonds into common shares. Therefore, as of June 25, 2026, the total amount applied for conversion by bondholders is NT\$0, and the cumulative number of common shares converted is 0 shares.</p>				

Attachment 6

2025 Directors' Compensation

2025 Directors and Independent Directors' Compensation

Unit: NT\$ thousands; %

Title	Name	Compensation of Directors								Amount and Ratio of Total Compensation (A+B+C+D) to Net Income (Loss) (%)		Relevant Compensation Received by Directors who are also Employees						Amount and Ratio of Total Compensation (A+B+C+D+E+F+G) to Net Income (Loss) (%)		Compensation Paid to Directors from an Invested Company Other than the Company's Subsidiary		
		Base Compensation (A)		Severance Pay (B)		Director's Compensation (C)		Allowances (D)				Salary, Bonuses, and Allowances (E)		Severance Pay (F)		Employees' Compensation (G)						
		The Company	Companies in the consolidated financial statements	The Company	Companies in the consolidated financial statements	The Company	Companies in the consolidated financial statements	The Company	Companies in the consolidated financial statements	The Company	Companies in the consolidated financial statements	The Company	Companies in the consolidated financial statements	The Company	Companies in the consolidated financial statements	The Company	Companies in the consolidated financial statements	The Company	Companies in the consolidated financial statements		The Company	Companies in the consolidated financial statements
Chairman & CEO	Foresee Pharmaceuticals, Inc.	-	-	-	-	-	-	88	88	88	88	5,738	19,140	-	-	-	-	-	-	5,826	19,228	None
	Representative: Ben Chien									(0.01)	(0.01)								(0.66)	(2.18)		
Director	Foresee Pharmaceuticals, Inc.	-	-	-	-	-	-	96	96	96	96	-	-	-	-	-	-	-	96	96	None	
	Representative: Vincent Yen									(0.01)	(0.01)								(0.01)	(0.01)		
Director & Chief Medical Officer	Foresee Pharmaceuticals, Inc.	-	-	-	-	-	-	96	96	96	96	-	13,960	-	-	-	-	-	96	14,056	None	
	Representative: Yisheng Lee									(0.01)	(0.01)								(0.01)	(1.59)		
Director	George Lee	-	-	-	-	-	-	96	96	96	96	-	-	-	-	-	-	-	96	96	None	
Director	Jeff Wang	-	-	-	-	-	-	96	96	96	96	-	-	-	-	-	-	-	96	96	None	
Independent Director	Fu-Shiow Yin	540	540	-	-	-	-	200	200	740	740	-	-	-	-	-	-	-	740	740	None	
Independent Director	Frank Lee	540	540	-	-	-	-	200	200	740	740	-	-	-	-	-	-	-	740	740	None	
Independent Director	Hank Lai	540	540	-	-	-	-	200	200	740	740	-	-	-	-	-	-	-	740	740	None	
Independent Director	Ben Liu	540	540	-	-	-	-	200	200	740	740	-	-	-	-	-	-	-	740	740	None	

**Independent Certified Public Accountant Report
and 2025 Financial Statements**

**FORESEE PHARMACEUTICALS CO., LTD.
AND SUBSIDIARIES
CONSOLIDATED FINANCIAL STATEMENTS WITH
INDEPENDENT AUDITORS' REPORT
DECEMBER 31, 2025 AND 2024**

For the convenience of readers and for information purpose only, the independent auditors' report and the accompanying financial statements have been translated into English from the original Chinese version prepared and used in the Republic of China. In the event of any discrepancy between the English version and the original Chinese version or any differences in the interpretation of the two versions, the Chinese-language independent auditors' report and financial statements shall prevail.

Independent Auditors' Report

To the Board of Directors and Shareholders of Foresee Pharmaceuticals Co., Ltd.

Opinion

We have audited the accompanying consolidated balance sheets of Foresee Pharmaceuticals Co., Ltd. and subsidiaries (the "Group") as at December 31, 2025 and 2024, and the related consolidated statements of comprehensive income, of changes in equity and of cash flows for the years then ended, and notes to the consolidated financial statements, including a summary of material accounting policies.

In our opinion, the accompanying consolidated financial statements present fairly, in all material respects, the consolidated financial position of the Group as at December 31, 2025 and 2024, and its consolidated financial performance and its consolidated cash flows for the years then ended in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and the International Financial Reporting Standards, International Accounting Standards, IFRIC Interpretations, and SIC Interpretations that came into effect as endorsed by the Financial Supervisory Commission.

Basis for opinion

We conducted our audits in accordance with the Regulations Governing Financial Statement Audit and Attestation Engagements of Certified Public Accountants and Standards on Auditing of the Republic of China. Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are independent of the Group in accordance with the Norm of Professional Ethics for Certified Public Accountant of the Republic of China, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key audit matters

Key audit matters are those matters that, in our professional judgement, were of most significance in our audit of the Group's 2025 consolidated financial statements. These matters were addressed in the context of our audit of the consolidated financial statements as a whole and, in forming our opinion thereon, we do not provide a separate opinion on these matters.

Key audit matter for the Group's 2025 consolidated financial statements is stated as follow:

Accuracy of licensing revenue and commissioned service revenue recognition

Description

Refer to Note 4(23) for accounting policies on licensing revenue, commissioned service and sales revenue, and Note 6(16) for the details of licensing revenue and commissioned service revenue.

For the year ended December 31, 2025, the Group derives revenue from licensing, commissioned service and sales revenue, among which, the licensing revenue and commissioned service revenue amounted to \$304,520 thousand. The recognition of licensing revenue is based on the terms of the agreement with the licensed party. The revenue is only recognised once all the criteria for the revenue recognition are met. The related key determinations are subject to the appropriateness of judgement on the agreements made by the management. The recognition of commissioned service revenue is based on the actual service provided as of the end of the reporting period in proportion to the total services to be provided. This is determined based on the actual costs incurred relative to the total estimated costs. The percentage of completion is subject to the appropriateness of judgement in the calculation of the costs made by the management. Given that the Group derives revenue primarily based on the above, we considered the accuracy of revenue recognition as the key audit matter.

How our audit addressed the matter

Our audit procedures performed in respect of the above key audit matter included:

1. Inspecting the contracts, obtaining the assessments and appropriate supporting documents, to ascertain whether licensing revenue and commissioned service revenue are two separate performance obligations.
2. Discussing with management the recognition policy to ascertain whether the licensing revenue and commissioned service revenue recognised were properly calculated, reviewed and approved.
3. Examining the terms of licensing contract and the calculation of the percentage of completion to assess the appropriateness of revenue recognition and ascertaining whether the accounting treatment adopted was in accordance with the related requirements.

Other matter - Parent company only financial reports

We have audited and expressed an unmodified opinion on the parent company only financial statements of Foresee Pharmaceuticals Co., Ltd. as at and for the years ended December 31, 2025 and 2024.

Responsibilities of management and those charged with governance for the consolidated financial statements

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and the International Financial Reporting Standards, International Accounting Standards, IFRIC Interpretations, and SIC Interpretations that came into effect as endorsed by the Financial Supervisory Commission, and for such internal control as management determines is necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, management is responsible for assessing the Group's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

Those charged with governance, including audit committee, are responsible for overseeing the Group's financial reporting process.

Auditors' responsibilities for the audit of the consolidated financial statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Standards on Auditing of the Republic of China will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

As part of an audit in accordance with the Standards on Auditing of the Republic of China, we exercise professional judgment and professional skepticism throughout the audit. We also:

1. Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
2. Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Group's internal control.
3. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
4. Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditors' report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditors' report. However, future events or conditions may cause the Group to cease to continue as a going concern.
5. Evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
6. Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Group to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the audit. We remain solely responsible for our audit opinion.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the consolidated financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditors' report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our auditors' report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Tsai, Pei-Hua

Yen, Yu-Fang

For and on behalf of PricewaterhouseCoopers, Taiwan

March 13, 2026

The accompanying consolidated financial statements are not intended to present the financial position and results of operations and cash flows in accordance with accounting principles generally accepted in countries and jurisdictions other than the Republic of China. The standards, procedures and practices in the Republic of China governing the review of such financial statements may differ from those generally accepted in countries and jurisdictions other than the Republic of China. Accordingly, the accompanying consolidated financial statements and auditors' report are not intended for use by those who are not informed about the accounting principles or Standards on Auditing of the Republic of China, and their applications in practice. As the consolidated financial statements are the responsibility of the management, PricewaterhouseCoopers cannot accept any liability for the use of, or reliance on, the English translation or for any errors or misunderstandings that may derive from the translation.

FORESEE PHARMACEUTICALS CO., LTD. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
DECEMBER 31, 2025 AND 2024
(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS)

	Assets	Notes	December 31, 2025		December 31, 2024	
			AMOUNT	%	AMOUNT	%
Current assets						
1100	Cash and cash equivalents	6(1)	\$ 479,518	36	\$ 1,367,299	63
1136	Financial assets at amortised cost	6(1)(3) and 8				
	- current		220,700	17	75,000	3
1170	Accounts receivable, net	6(4)	43,484	3	32,328	2
1200	Other receivables		225	-	3,810	-
1220	Current income tax assets		9,006	1	9,948	-
130X	Inventories	6(5)	144,707	11	183,874	9
1410	Prepayments	6(2) and 7	88,071	7	145,273	7
11XX	Total current assets		<u>985,711</u>	<u>75</u>	<u>1,817,532</u>	<u>84</u>
Non-current assets						
1600	Property, plant and equipment	6(6) and 8	172,459	13	205,951	10
1755	Right-of-use assets	6(7)	34,697	3	11,668	1
1780	Intangible assets	6(8)	111,140	9	117,791	5
1840	Deferred income tax assets	6(23)	1,253	-	1,307	-
1915	Prepayments for business facilities		2,986	-	3,305	-
1920	Guarantee deposits paid		2,145	-	1,598	-
15XX	Total non-current assets		<u>324,680</u>	<u>25</u>	<u>341,620</u>	<u>16</u>
1XXX	Total assets		<u>\$ 1,310,391</u>	<u>100</u>	<u>\$ 2,159,152</u>	<u>100</u>
Liabilities and Equity						
Current liabilities						
2100	Short-term borrowings	6(9)	\$ 197,000	15	\$ 150,000	7
2130	Contract liabilities - current	6(16)	-	-	50,030	2
2170	Accounts payable		16,570	1	64,418	3
2200	Other payables		39,472	3	87,574	4
2220	Other payables - related parties	7	7,313	1	5,370	-
2230	Current income tax liabilities		11,474	1	8,822	-
2280	Lease liabilities - current		14,233	1	12,408	1
2320	Long-term liabilities - current portion	6(10)	-	-	5,000	-
2399	Other current liabilities		242	-	9,587	1
21XX	Total current liabilities		<u>286,304</u>	<u>22</u>	<u>393,209</u>	<u>18</u>
Non-current liabilities						
2527	Contract liabilities - non-current	6(16)	72,620	5	72,620	4
2540	Long-term borrowings	6(10)	-	-	92,917	4
2570	Deferred income tax liabilities	6(23)	1,348	-	1,406	-
2580	Lease liabilities - non-current		20,505	2	-	-
25XX	Total non-current liabilities		<u>94,473</u>	<u>7</u>	<u>166,943</u>	<u>8</u>
2XXX	Total liabilities		<u>380,777</u>	<u>29</u>	<u>560,152</u>	<u>26</u>
Equity						
Share capital						
3110	Common shares	6(13)	1,575,375	120	1,547,878	72
Capital surplus						
3200	Capital surplus	6(14)	6,086,886	465	5,906,317	274
Accumulated deficit						
3350	Deficit yet to be compensated	6(15)	(6,693,790)	(511)	(5,810,639)	(269)
Other equity						
3400	Other equity interest		(38,857)	(3)	(44,556)	(3)
31XX	Equity attributable to shareholders of the parent		<u>929,614</u>	<u>71</u>	<u>1,599,000</u>	<u>74</u>
3XXX	Total equity		<u>929,614</u>	<u>71</u>	<u>1,599,000</u>	<u>74</u>
Significant contingent liabilities and unrecognised contract commitments 9						
Significant events after the balance sheet date 11						
3X2X	Total liabilities and equity		<u>\$ 1,310,391</u>	<u>100</u>	<u>\$ 2,159,152</u>	<u>100</u>

The accompanying notes are an integral part of these consolidated financial statements.

FORESEE PHARMACEUTICALS CO., LTD. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, EXCEPT LOSS PER SHARE DATA)

Items	Notes	For the years ended December 31,			
		2025		2024	
		AMOUNT	%	AMOUNT	%
4000 Operating revenue	6(16)	\$ 431,274	100	\$ 418,689	100
5000 Operating costs	6(5)(6)(8)(21) (22)	(137,057)	(32)	(178,888)	(43)
5900 Net operating margin		<u>294,217</u>	<u>68</u>	<u>239,801</u>	<u>57</u>
Operating expenses	6(6)(7)(8)(11) (12)(21)(22) and 7				
6100 Selling expenses		(24,971)	(6)	(20,811)	(5)
6200 General and administrative expenses		(156,432)	(36)	(126,507)	(30)
6300 Research and development expenses		(975,130)	(226)	(1,172,273)	(280)
6000 Total operating expenses		(1,156,533)	(268)	(1,319,591)	(315)
6900 Operating loss		(862,316)	(200)	(1,079,790)	(258)
Non-operating income and expenses					
7100 Interest income	6(3)(17)	18,174	4	28,281	7
7010 Other income	6(18)	9,172	2	3,260	1
7020 Other gains and losses	6(19)	(17,666)	(4)	21,754	5
7050 Finance costs	6(7)(9)(10)(20)	(5,567)	(1)	(6,708)	(2)
7000 Total non-operating income and expenses		<u>4,113</u>	<u>1</u>	<u>46,587</u>	<u>11</u>
7900 Loss before income tax		(858,203)	(199)	(1,033,203)	(247)
7950 Income tax expense	6(23)	(24,948)	(6)	(47,869)	(11)
8200 Loss for the year		<u>(\$ 883,151)</u>	<u>(205)</u>	<u>(\$ 1,081,072)</u>	<u>(258)</u>
Other comprehensive income (loss)					
Components of other comprehensive income that will be reclassified to profit or loss					
8361 Financial statements translation differences of foreign operations		(\$ 18,154)	(4)	\$ 8,108	2
8300 Other comprehensive (loss) income for the year		<u>(\$ 18,154)</u>	<u>(4)</u>	<u>\$ 8,108</u>	<u>2</u>
8500 Total comprehensive loss for the year		<u>(\$ 901,305)</u>	<u>(209)</u>	<u>(\$ 1,072,964)</u>	<u>(256)</u>
Loss attributable to:					
8610 Shareholders of the parent		<u>(\$ 883,151)</u>	<u>(205)</u>	<u>(\$ 1,081,072)</u>	<u>(258)</u>
Comprehensive loss attributable to:					
8710 Shareholders of the parent		<u>(\$ 901,305)</u>	<u>(209)</u>	<u>(\$ 1,072,964)</u>	<u>(256)</u>
Basic loss per share (in dollars)	6(24)				
9750 Loss per share		<u>(\$ 5.70)</u>		<u>(\$ 7.87)</u>	
Diluted loss per share (in dollars)	6(24)				
9850 Loss per share		<u>(\$ 5.70)</u>		<u>(\$ 7.87)</u>	

The accompanying notes are an integral part of these consolidated financial statements.

FORESEE PHARMACEUTICALS CO., LTD. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024
(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS)

	Equity attributable to shareholders of the parent										
	Notes	Capital Surplus					Other Equity Interest				Total equity
		Common shares	Share premium	Difference between consideration and carrying amount of subsidiaries acquired or disposed	Employee stock options	Employee restricted stocks	Others	Deficit yet to be compensated	Financial statements translation differences of foreign operations	Unearned employee compensation	
For the year ended December 31, 2024											
Balance at January 1, 2024		\$ 1,358,173	\$ 4,453,783	\$ 21,984	\$ 135,197	\$ -	\$ 6,432	(\$ 4,729,567)	(\$ 1,490)	\$ -	\$ 1,244,512
Loss for the year		-	-	-	-	-	-	(1,081,072)	-	-	(1,081,072)
Other comprehensive income for the year		-	-	-	-	-	-	-	8,108	-	8,108
Total comprehensive (loss) income for the year		-	-	-	-	-	-	(1,081,072)	8,108	-	(1,072,964)
Compensation cost of employee stock options	6(12)(22)	-	-	-	34,302	-	-	-	-	-	34,302
Issuance of common shares for cash	6(13)	180,000	1,185,098	-	(518)	-	-	-	-	-	1,364,580
Employee stock options exercised	6(12)(13)	1,805	14,655	-	(3,405)	-	-	-	-	-	13,055
Employee stock options expired		-	-	-	(8,316)	-	8,316	-	-	-	-
Issuance of employee restricted stocks	6(12)(13)	8,200	-	-	-	61,024	-	-	-	(69,224)	-
Capital reduction through retirement and adjustment due to resignation of employee restricted stocks forfeited	6(12)(13)	(300)	-	-	-	(2,235)	-	-	-	2,535	-
Compensation cost of employee restricted stocks	6(12)(22)	-	-	-	-	-	-	-	-	15,515	15,515
Balance at December 31, 2024		\$ 1,547,878	\$ 5,653,536	\$ 21,984	\$ 157,260	\$ 58,789	\$ 14,748	(\$ 5,810,639)	\$ 6,618	(\$ 51,174)	\$ 1,599,000
For the year ended December 31, 2025											
Balance at January 1, 2025		\$ 1,547,878	\$ 3,653,536	\$ 21,984	\$ 157,260	\$ 58,789	\$ 14,748	(\$ 5,810,639)	(\$ 6,618)	(\$ 51,174)	\$ 1,599,000
Loss for the year		-	-	-	-	-	-	(883,151)	-	-	(883,151)
Other comprehensive loss for the year		-	-	-	-	-	-	-	(18,154)	-	(18,154)
Total comprehensive loss for the year		-	-	-	-	-	-	(883,151)	(18,154)	-	(901,305)
Compensation cost of employee stock options	6(12)(22)	-	-	-	14,270	-	-	-	-	-	14,270
Issuance of common shares for cash	6(13)	25,000	155,000	-	-	-	-	-	-	-	180,000
Employee stock options exercised	6(12)(13)	2,977	20,901	-	(5,650)	-	-	-	-	-	18,228
Employee stock options expired		-	-	-	(22,684)	-	22,684	-	-	-	-
Issuance of employee restricted stocks	6(12)(13)	800	-	-	-	5,584	-	-	-	(6,384)	-
Capital reduction through retirement and adjustment due to resignation of employee restricted stocks forfeited	6(12)(13)	(1,280)	-	-	-	(9,536)	-	-	-	10,816	-
Compensation cost of employee restricted stocks	6(12)(22)	-	-	-	-	-	-	-	-	19,421	19,421
Balance at December 31, 2025		\$ 1,575,375	\$ 5,829,437	\$ 21,984	\$ 143,196	\$ 54,837	\$ 37,432	(\$ 6,693,790)	(\$ 11,536)	(\$ 27,321)	\$ 929,614

The accompanying notes are an integral part of these consolidated financial statements.

FORESEE PHARMACEUTICALS CO., LTD. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024
(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS)

	Notes	For the years ended December 31,	
		2025	2024
<u>CASH FLOWS FROM OPERATING ACTIVITIES</u>			
Loss before income tax		(\$ 858,203)	(\$ 1,033,203)
Reconciling items			
Adjustments to reconcile profit (loss)			
Depreciation	6(6)(7)(21)	48,947	65,141
Amortisation	6(8)(21)	19,187	15,379
Interest expense	6(20)	5,567	6,708
Interest income	6(17)	(18,174)	(28,281)
Compensation cost of share-based payment	6(12)(22)	33,691	49,817
Loss on disposal of property, plant and equipment	6(19)	-	30
Gain arising from lease modifications		-	(228)
Changes in assets and liabilities relating to operating activities			
Changes in assets relating to operating activities			
Accounts receivable, net		(11,156)	33,584
Other receivables		2,490	(2,572)
Inventories		39,167	(57,075)
Prepayments		61,078	(108,624)
Changes in liabilities relating to operating activities			
Contract liabilities		(50,030)	(114,496)
Accounts payable		(47,848)	52,285
Other payables		(47,959)	(21,770)
Other payables - related parties		1,943	(10,049)
Other current liabilities		(9,345)	9,350
Cash outflow generated from operations		(830,645)	(1,144,004)
Receipt of interest		19,269	28,437
Payment of interest		(5,621)	(6,469)
Payment of income tax		(25,230)	(51,714)
Net cash flows used in operating activities		(842,227)	(1,173,750)
<u>CASH FLOWS FROM INVESTING ACTIVITIES</u>			
Acquisition of financial assets at amortised cost - current		(220,700)	(75,000)
Proceeds from disposal of financial assets at amortised cost - current		75,000	342,500
Acquisition of property, plant and equipment	6(25)	(2,963)	(148,295)
Proceeds from disposal of property, plant and equipment		-	211
Acquisition of intangible assets	6(8)	(12,536)	(6,357)
Increase in prepayments for business facilities		-	(1,299)
(Increase) decrease in guarantee deposits		(547)	1,062
Net cash flows used in (from) investing activities		(161,746)	112,822
<u>CASH FLOWS FROM FINANCING ACTIVITIES</u>			
Increase in short-term borrowings	6(26)	600,000	800,000
Decrease in short-term borrowings	6(26)	(553,000)	(850,000)
Proceeds from long-term borrowings	6(26)	-	100,000
Repayment of long-term borrowings	6(26)	(97,917)	(2,083)
Issuance of shares for cash	6(13)	180,000	1,364,580
Repayment of lease liabilities	6(26)	(13,132)	(15,005)
Employee stock options exercised		18,228	13,055
Net cash flows from financing activities		134,179	1,410,547
Effects due to changes in exchange rate		(17,987)	8,001
Net (decrease) increase in cash and cash equivalents		(887,781)	357,620
Cash and cash equivalents at beginning of year		1,367,299	1,009,679
Cash and cash equivalents at end of year		\$ 479,518	\$ 1,367,299

The accompanying notes are an integral part of these consolidated financial statements.

FORESEE PHARMACEUTICALS CO., LTD.
PARENT COMPANY ONLY FINANCIAL
STATEMENTS WITH INDEPENDENT AUDITORS’
REPORT
DECEMBER 31, 2025 AND 2024

For the convenience of readers and for information purpose only, the independent auditors’ report and the accompanying financial statements have been translated into English from the original Chinese version prepared and used in the Republic of China. In the event of any discrepancy between the English version and the original Chinese version or any differences in the interpretation of the two versions, the Chinese-language independent auditors’ report and financial statements shall prevail.

Independent Auditors' Report

To the Board of Directors and Shareholders of Foresee Pharmaceuticals Co., Ltd.

Opinion

We have audited the accompanying parent company only balance sheets of Foresee Pharmaceuticals Co., Ltd. (the "Company") as at December 31, 2025 and 2024, and the related parent company only statements of comprehensive income, of changes in equity and of cash flows for the years then ended, and notes to the parent company only financial statements, including a summary of material accounting policies.

In our opinion, the accompanying parent company only financial statements present fairly, in all material respects, the financial position of Foresee Pharmaceuticals Co., Ltd. as at December 31, 2025 and 2024, and its financial performance and its cash flows for the years then ended in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers.

Basis for opinion

We conducted our audits in accordance with the Regulations Governing Financial Statement Audit and Attestation Engagements of Certified Public Accountants and Standards on Auditing of the Republic of China. Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Parent Company Only Financial Statements section of our report. We are independent of the Company in accordance with the Norm of Professional Ethics for Certified Public Accountant of the Republic of China, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key audit matters

Key audit matters are those matters that, in our professional judgement, were of most significance in our audit of the Company's 2025 parent company only financial statements. These matters were addressed in the context of our audit of the parent company only financial statements as a whole and, in forming our opinion thereon, we do not provide a separate opinion on these matters.

Key audit matter for the Company's 2025 parent company only financial statements is stated as follow:

Accuracy of licensing revenue and commissioned service revenue recognition

Description

Refer to Note 4(23) for accounting policies on licensing revenue and commissioned service revenue, and Note 6(17) for the details of licensing revenue and commissioned service revenue.

For the year ended December 31, 2025, the Company derives revenue from licensing, commissioned service and sales revenue, among which, the licensing revenue and commissioned service revenue amounted to \$346,069 thousand. The recognition of licensing revenue is based on the terms of the agreement with the licensed party. The revenue is only recognised once all the criteria for the revenue recognition are met. The related key determinations are subject to the appropriateness of judgement on the agreements made by the management. The recognition of commissioned service revenue is based on the actual service provided as of the end of the reporting period in proportion to the total services to be provided. This is determined based on the actual costs incurred relative to the total estimated costs. The percentage of completion is subject to the appropriateness of judgement in the calculation of the costs made by the management. Given that the Company derives revenue primarily based on the above, we considered the accuracy of revenue recognition as the key audit matter.

How our audit addressed the matter

Our audit procedures performed in respect of the above key audit matter included:

1. Inspecting the contracts, obtaining the assessments and appropriate supporting documents, to ascertain whether licensing revenue and commissioned service revenue are two separate performance obligations.
2. Discussing with management the recognition policy to ascertain whether the licensing revenue and commissioned service revenue recognised were properly calculated, reviewed and approved.
3. Examining the terms of licensing contract and the calculation of the percentage of completion to assess the appropriateness of revenue recognition and ascertaining whether the accounting treatment adopted was in accordance with the related requirements.

Responsibilities of management and those charged with governance for the parent company only financial statements

Management is responsible for the preparation and fair presentation of the parent company only financial statements in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers, and for such internal control as management determines is necessary to enable the preparation of parent company only financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the parent company only financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those charged with governance, including audit committee, are responsible for overseeing the Company's financial reporting process.

Auditors' responsibilities for the audit of the parent company only financial statements

Our objectives are to obtain reasonable assurance about whether the parent company only financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Standards on Auditing of the Republic of China will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these parent company only financial statements.

As part of an audit in accordance with the Standards on Auditing of the Republic of China, we exercise professional judgment and professional skepticism throughout the audit. We also:

1. Identify and assess the risks of material misstatement of the parent company only financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the

override of internal control.

2. Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
3. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
4. Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditors' report to the related disclosures in the parent company only financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditors' report. However, future events or conditions may cause the Company to cease to continue as a going concern.
5. Evaluate the overall presentation, structure and content of the parent company only financial statements, including the disclosures, and whether the parent company only financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
6. Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Company to express an opinion on the parent company only financial statements. We are responsible for the direction, supervision and performance of the audit. We remain solely responsible for our audit opinion.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the parent company only financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditors' report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our auditors' report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Tsai, Pei-Hua

Yen, Yu-Fang

For and on behalf of PricewaterhouseCoopers, Taiwan

March 13, 2026

The accompanying separate financial statements are not intended to present the financial position and results of operations and cash flows in accordance with accounting principles generally accepted in countries and jurisdictions other than the Republic of China. The standards, procedures and practices in the Republic of China governing the audit of such financial statements may differ from those generally accepted in countries and jurisdictions other than the Republic of China. Accordingly, the accompanying parent company only financial statements and auditors' report are not intended for use by those who are not informed about the accounting principles or Standards on Auditing of the Republic of China, and their applications in practice. As the parent company only financial statements are the responsibility of the management, PricewaterhouseCoopers cannot accept any liability for the use of, or reliance on, the English translation or for any errors or misunderstandings that may derive from the translation.

FORESEE PHARMACEUTICALS CO., LTD.
PARENT COMPANY ONLY BALANCE SHEETS
DECEMBER 31, 2025 AND 2024
(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS)

Assets	Notes	December 31, 2025		December 31, 2024		
		Amount	%	Amount	%	
Current assets						
1100	Cash and cash equivalents	6(1)	\$ 277,291	22	\$ 1,305,311	60
1136	Financial assets at amortised cost - current	6(1)(3) and 8	220,700	17	75,000	3
1170	Accounts receivable, net	6(4)	43,484	4	32,328	2
1180	Accounts receivable - related parties, net	7	3,348	-	3,682	-
1200	Other receivables		225	-	3,810	-
1220	Current income tax assets		3,658	-	3,855	-
130X	Inventories	6(5)	144,707	11	183,874	8
1410	Prepayments	6(2) and 7	85,258	7	127,442	6
11XX	Total current assets		<u>778,671</u>	<u>61</u>	<u>1,735,302</u>	<u>79</u>
Non-current assets						
1550	Investments accounted for under equity method	6(6)	197,060	15	129,697	6
1600	Property, plant and equipment	6(7) and 8	169,095	13	201,733	9
1755	Right-of-use assets	6(8)	19,568	2	4,193	-
1780	Intangible assets	6(9)	111,140	9	117,472	6
1915	Prepayments for business facilities		2,986	-	3,305	-
1920	Guarantee deposits paid		1,478	-	1,478	-
15XX	Total non-current assets		<u>501,327</u>	<u>39</u>	<u>457,878</u>	<u>21</u>
1XXX	Total assets		<u>\$ 1,279,998</u>	<u>100</u>	<u>\$ 2,193,180</u>	<u>100</u>
Liabilities and Equity						
Current liabilities						
2100	Short-term borrowings	6(10)	\$ 197,000	15	\$ 150,000	7
2130	Contract liabilities - current	6(17)	-	-	50,030	2
2170	Accounts payable		7,998	1	64,418	3
2180	Accounts payable - related parties	7	8,572	1	8,628	-
2200	Other payables		21,228	2	63,370	3
2220	Other payables - related parties	7	11,650	1	64,062	3
2230	Current income tax liabilities		11,474	1	8,822	-
2280	Lease liabilities - current		6,763	-	4,727	-
2320	Long-term liabilities - current portion	6(11)	-	-	5,000	-
2399	Other current liabilities		233	-	9,586	1
21XX	Total current liabilities		<u>264,918</u>	<u>21</u>	<u>428,643</u>	<u>19</u>
Non-current liabilities						
2527	Contract liabilities - non-current	6(17)	72,620	5	72,620	4
2540	Long-term borrowings	6(11)	-	-	92,917	4
2580	Lease liabilities - non-current		12,846	1	-	-
25XX	Total non-current liabilities		<u>85,466</u>	<u>6</u>	<u>165,537</u>	<u>8</u>
2XXX	Total liabilities		<u>350,384</u>	<u>27</u>	<u>594,180</u>	<u>27</u>
Equity						
Share capital						
3110	Common shares	6(14)	1,575,375	123	1,547,878	70
Capital surplus						
3200	Capital surplus	6(15)	6,086,886	476	5,906,317	270
Accumulated deficit						
3350	Deficit yet to be compensated	6(16)	(6,693,790)	(523)	(5,810,639)	(265)
Other equity interest						
3400	Other equity interest		(38,857)	(3)	(44,556)	(2)
3XXX	Total equity		<u>929,614</u>	<u>73</u>	<u>1,599,000</u>	<u>73</u>
Significant contingent liabilities and unrecognised contract commitments						
Significant events after the balance sheet date						
3X2X	Total liabilities and equity		<u>\$ 1,279,998</u>	<u>100</u>	<u>\$ 2,193,180</u>	<u>100</u>

The accompanying notes are an integral part of these parent company only financial statements.

FORESEE PHARMACEUTICALS CO., LTD.
PARENT COMPANY ONLY STATEMENTS OF COMPREHENSIVE INCOME
FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024
(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, EXCEPT LOSS PER SHARE DATA)

Items	Notes	For the years ended December 31,				
		2025		2024		
		Amount	%	Amount	%	
4000	Operating revenue	6(17) and 7	\$ 472,823	100	\$ 449,493	100
5000	Operating costs	6(5)(7)(9)(22) (23)	(137,057)	(29)	(178,888)	(40)
5900	Net operating margin		335,766	71	270,605	60
	Operating expenses	6(7)(8)(9)(12) (13)(22)(23) and 7				
6100	Selling expenses		(13,641)	(3)	(11,612)	(3)
6200	General and administrative expenses		(90,090)	(19)	(91,230)	(20)
6300	Research and development expenses		(722,676)	(153)	(853,886)	(190)
6000	Total operating expenses		(826,407)	(175)	(956,728)	(213)
6900	Operating loss		(490,641)	(104)	(686,123)	(153)
	Non-operating income and expenses					
7100	Interest income	6(3)(18)	14,620	3	23,957	5
7010	Other income	6(19)	8,591	2	3,260	1
7020	Other gains and losses	6(20) and 7	(17,580)	(4)	702,529	156
7050	Finance costs	6(8)(10)(11)(21)	(5,468)	(1)	(6,420)	(1)
7070	Share of profit of subsidiaries, associates and joint ventures accounted for under equity method	6(6)	(343,679)	(73)	(1,081,635)	(241)
7000	Total non-operating income and expenses		(343,516)	(73)	(358,309)	(80)
7900	Loss before income tax		(834,157)	(177)	(1,044,432)	(233)
7950	Income tax expense	6(24)	(48,994)	(10)	(36,640)	(8)
8200	Loss for the year		(\$ 883,151)	(187)	(\$ 1,081,072)	(241)
	Components of other comprehensive income that will be reclassified to profit or loss					
8361	Financial statements translation differences of foreign operations	6(6)	(\$ 18,154)	(4)	\$ 8,108	2
8300	Other comprehensive (loss) income for the year		(\$ 18,154)	(4)	\$ 8,108	2
8500	Total comprehensive loss for the year		(\$ 901,305)	(191)	(\$ 1,072,964)	(239)
	Basic loss per share (in dollars)	6(25)				
9750	Loss per share		(\$ 5.70)		(\$ 7.87)	
	Diluted loss per share (in dollars)	6(25)				
9850	Loss per share		(\$ 5.70)		(\$ 7.87)	

The accompanying notes are an integral part of these parent company only financial statements.

FORESEE PHARMACEUTICALS CO., LTD.
PARENT COMPANY ONLY STATEMENTS OF CHANGES IN EQUITY
FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024
(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS)

	Equity attributable to shareholders of the parent										
	Notes	Capital Surplus						Other Equity Interest			Total equity
		Common shares	Share premium	Difference between consideration and carrying amount of subsidiaries acquired or disposed	Employee stock options	Employee restricted stocks	Others	Deficit yet to be compensated	Financial statements translation differences of foreign operations	Unearned employee compensation	
For the year ended December 31, 2024											
Balance at January 1, 2024		\$ 1,358,173	\$ 4,453,783	\$ 21,984	\$ 135,197	\$ -	\$ 6,432	(\$ 4,729,567)	(\$ 1,490)	\$ -	\$ 1,244,512
Loss for the year		-	-	-	-	-	-	(1,081,072)	-	-	(1,081,072)
Other comprehensive income for the year	6(6)	-	-	-	-	-	-	-	8,108	-	8,108
Total comprehensive (loss) income for the year		-	-	-	-	-	-	(1,081,072)	8,108	-	(1,072,964)
Compensation cost of employee stock options	6(13)(23)	-	-	-	34,302	-	-	-	-	-	34,302
Issuance of common shares for cash	6(14)	180,000	1,185,098	-	(518)	-	-	-	-	-	1,364,580
Employee stock options exercised	6(13)(14)	1,805	14,655	-	(3,405)	-	-	-	-	-	13,055
Employee stock options expired		-	-	-	(8,316)	-	8,316	-	-	-	-
Issuance of employee restricted stocks	6(13)(14)	8,200	-	-	-	61,024	-	-	-	(69,224)	-
Capital reduction through retirement and adjustment due to resignation of employee restricted stocks forfeited	6(13)(14)	(300)	-	-	-	(2,235)	-	-	-	2,535	-
Compensation cost of employee restricted stocks	6(13)(23)	-	-	-	-	-	-	-	-	15,515	15,515
Balance at December 31, 2024		\$ 1,547,878	\$ 5,653,536	\$ 21,984	\$ 157,260	\$ 58,789	\$ 14,748	(\$ 5,810,639)	\$ 6,618	(\$ 51,174)	\$ 1,599,000
For the year ended December 31, 2025											
Balance at January 1, 2025		\$ 1,547,878	\$ 5,653,536	\$ 21,984	\$ 157,260	\$ 58,789	\$ 14,748	(\$ 5,810,639)	(\$ 6,618)	(\$ 51,174)	\$ 1,599,000
Loss for the year		-	-	-	-	-	-	(883,151)	-	-	(883,151)
Other comprehensive loss for the year	6(6)	-	-	-	-	-	-	-	(18,154)	-	(18,154)
Total comprehensive loss for the year		-	-	-	-	-	-	(883,151)	(18,154)	-	(901,305)
Compensation cost of employee stock options	6(13)(23)	-	-	-	14,270	-	-	-	-	-	14,270
Issuance of common shares for cash	6(14)	25,000	155,000	-	-	-	-	-	-	-	180,000
Employee stock options exercised	6(13)(14)	2,977	20,901	-	(5,650)	-	-	-	-	-	18,228
Employee stock options expired		-	-	-	(22,684)	-	22,684	-	-	-	-
Issuance of employee restricted stocks	6(13)(14)	800	-	-	-	5,584	-	-	-	(6,384)	-
Capital reduction through retirement and adjustment due to resignation of employee restricted stocks forfeited	6(13)(14))	(1,280)	-	-	-	(9,536)	-	-	-	10,816	-
Compensation cost of employee restricted stocks	6(13)(23)	-	-	-	-	-	-	-	-	19,421	19,421
Balance at December 31, 2025		\$ 1,575,375	\$ 5,829,437	\$ 21,984	\$ 143,196	\$ 54,837	\$ 37,432	(\$ 6,693,790)	(\$ 11,536)	(\$ 27,321)	\$ 929,614

The accompanying notes are an integral part of these parent company only financial statements.

FORESEE PHARMACEUTICALS CO., LTD.
PARENT COMPANY ONLY STATEMENTS OF CASH FLOWS
FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024
(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS)

	Notes	For the years ended December 31,	
		2025	2024
<u>CASH FLOWS FROM OPERATING ACTIVITIES</u>			
Loss before income tax		(\$ 834,157)	(\$ 1,044,432)
Reconciling items			
Adjustments to reconcile profit (loss)			
Depreciation	6(7)(8)(22)	40,650	56,650
Amortisation	6(9)(22)	18,868	14,969
Interest expense	6(21)	5,468	6,420
Interest income	6(18)	(14,620)	(23,957)
Compensation cost of share-based payments	6(13)(23)	9,180	16,101
Share of loss of subsidiaries accounted for under equity method	6(6)	343,679	1,081,635
Loss on disposal of property, plant and equipment	6(20)	-	30
Gain on disposal of intangible assets	6(20) and 7	-	(680,698)
Gain arising from lease modifications		-	(228)
Changes in assets and liabilities relating to operating activities			
Changes in assets relating to operating activities			
Accounts receivable, net		(11,156)	33,584
Accounts receivable - related parties		334	(3,682)
Inventories		39,167	(57,075)
Other receivables		2,490	(2,572)
Prepayments		42,184	(91,586)
Changes in liabilities relating to operating activities			
Contract liabilities		(50,030)	(114,496)
Accounts payable		(56,420)	52,285
Accounts payable - related parties		(56)	8,628
Other payables		(41,999)	(28,477)
Other payables - related parties		(52,412)	28,292
Other current liabilities		(9,353)	9,349
Cash outflow generated from operating activities		(568,183)	(739,260)
Receipt of interest		15,715	24,113
Payment of interest		(5,522)	(6,181)
Payment of income tax		(46,145)	(40,180)
Net cash flows used in operating activities		(604,135)	(761,508)
<u>CASH FLOWS FROM INVESTING ACTIVITIES</u>			
Acquisition of financial assets at amortised cost - current		(220,700)	(75,000)
Proceeds from disposal of financial assets at amortised cost - current		75,000	342,500
Acquisition of ownership interests in subsidiaries	6(6)	(404,685)	(335,053)
Acquisition of property, plant and equipment	6(26)	(2,438)	(145,061)
Proceeds from disposal of property, plant and equipment		-	211
Acquisition of intangible assets	6(9)	(12,536)	(6,357)
Increase in prepayments for business facilities		-	(1,299)
Decrease in guarantee deposits		-	941
Net cash flows used in investing activities		(565,359)	(219,118)
<u>CASH FLOWS FROM FINANCING ACTIVITIES</u>			
Increase in short-term borrowings	6(27)	600,000	800,000
Decrease in short-term borrowings	6(27)	(553,000)	(850,000)
Proceeds from long-term borrowings	6(27)	-	100,000
Repayment of long-term borrowings	6(27)	(97,917)	(2,083)
Issuance of common shares for cash	6(14)	180,000	1,364,580
Repayment of lease liabilities	6(27)	(5,837)	(7,663)
Employee stock options exercised		18,228	13,055
Net cash flows from financing activities		141,474	1,417,889
Net (decrease) increase in cash and cash equivalents		(1,028,020)	437,263
Cash and cash equivalents at beginning of year		1,305,311	868,048
Cash and cash equivalents at end of year		\$ 277,291	\$ 1,305,311

The accompanying notes are an integral part of these parent company only financial statements.

Attachment 8

Concurrent Position Newly Held by Director

Director	Company Name and Concurrent Positions Newly Held
Foresee Pharmaceuticals, Inc. Representative: Ben Chien	Director of Primevera Therapeutics, LLC

**Relevant Information on the Issuance of Common
Shares Through Cash Capital Increase for
Sponsoring Global Depository Receipt Issuance
and/or Conducting a Cash Capital Increase via
Book-Building or Auction Methods**

Relevant Information on the Issuance of Common Shares Through Cash Capital Increase for Sponsoring Global Depository Receipt Issuance and/or Conducting a Cash Capital Increase via Book-Building or Auction Methods

I. Issuance of Common Shares Through Cash Capital Increase for Sponsoring the Issuance of Global Depository Receipts (GDRs):

1. With respect to this cash capital increase for the purpose of sponsoring the issuance of GDRs, apart from reserving 10% to 15% of the total new shares to be subscribed by employees in accordance with applicable laws, it is proposed that, pursuant to Article 28-1 of the Securities and Exchange Act, the shareholders' meeting approve a waiver of preemptive rights by existing shareholders, so that all remaining new shares may be allocated for public offering through GDR issuance. In the event that employees waive their rights or do not fully subscribe to their allocated shares, the Chairman is authorized to include such unsubscribed shares as underlying securities for the GDRs or allocate them to specific parties through private placement as necessary based on market conditions.
2. The pricing of the common shares to be issued for GDR purposes will be determined with reference to:
 - (a) the closing price of the Company's common shares on the pricing date, or
 - (b) the simple arithmetic average of the closing prices of the Company's common shares for any one of the 1, 3, or 5 business days preceding the pricing date (collectively referred to as the "Reference Price").

The actual issue price shall not be lower than 90% of the Reference Price after adjustment for any stock dividends or capital reduction. However, the final issue price is authorized to be jointly determined by the Chairman and the lead underwriters based on prevailing market conditions. The aforementioned determination of the Reference Price and actual issue price complies with market practices and legal regulations. Assuming a maximum issuance of 35,000,000 common shares, this represents 22.2% of the Company's outstanding common shares as of the book closure date for the 2025 Extraordinary General Meeting. Given that the actual issue price must not be lower than 90% of the Reference Price (after adjusting for stock dividends, capital reduction, or cash dividends), there should be no significant dilution of existing shareholders' equity. Therefore, the pricing of the GDR is considered reasonable and is not expected to have a material impact on existing shareholders' interests.

II. Issuance of Common Shares Through Cash Capital Increase via Book-Building or Auction Methods in the Domestic Market:

1. In accordance with Article 267, Paragraph 1 of the Company Act, 10% to 15% of the total number of new shares to be issued through this cash capital increase shall be reserved for subscription by employees at the issue price. The remaining shares are proposed to be fully allocated for public offering through book-building or competitive auction methods, subject to shareholder approval to waive preemptive rights pursuant to Article 28-1 of the Securities and Exchange Act. In the event that employees waive their rights or do not fully subscribe to their allocated shares, the Chairman is authorized to allocate such unsubscribed shares to specific parties at the issue price.
2. The issue price shall be determined in accordance with the relevant regulations set forth in the "Self-Regulatory Rules for Underwriters Assisting Issuers in Raising and Issuing

Securities” of the Taipei Exchange. At the time of filing the offering with the Financial Supervisory Commission, submitting the book-building agreement to the Taipei Exchange, announcing the competitive auction, or submitting the underwriting agreement, the issue price must not be lower than 90% of the simple arithmetic average of the closing prices of the Company’s common shares for any one of the 1, 3, or 5 business days preceding the pricing date, after adjusting for any ex-dividend or ex-rights events (including stock dividends or capital reduction). The final issue price is authorized to be jointly determined by the Chairman and the underwriters based on prevailing market conditions at the time of issuance.

【Appendix 1】

Articles of Incorporation

Foresee Pharmaceuticals Co., Ltd.

Articles of Incorporation

Chapter I General Provisions

- Article 1 The Company shall be named Foresee Pharmaceuticals Co., Ltd. and incorporated as a company limited by shares in accordance with the Company Act (the “Company Act”) of the Republic of China (the “R.O.C.”).
- Article 2 The Company will engage in
- F108040 Wholesale of Cosmetics.
 - F208040 Retail Sale of Cosmetics.
 - F108021 Wholesale of Drugs and Medicines.
 - F208021 Retail Sale of Drugs and Medicines.
 - F208050 Retail Sale of Second Type Patent Medicine.
 - F401010 International Trade.
 - F601010 Intellectual Property.
 - I101090 Food Consultancy.
 - I102010 Investment Consultancy.
 - I103060 Management Consulting Services.
 - I301030 Digital Information Supply Services.
 - IC01010 Pharmaceuticals Testing Services.
 - IG01010 Biotechnology Services.
 - IG02010 Research Development Service.
 - IZ12010 Manpower Services.
 - IZ15010 Marketing Research and Opinion Polling.
 - ZZ99999 Any business not prohibited or restricted by law or other than types of business requiring special permission.
- Article 3 Due to the operational or investment needs of the Company, the Company may provide endorsements or guarantees to others in accordance with the “Procedures for Endorsements and Guarantees” of the Company.

Unless otherwise stipulated in Article 15 of the Company Act, the capital of the Company shall not be lent to any shareholder of the Company or any other person.

Article 4 The Company may make investments in another company through acting as a shareholder with limited liability of the invested company, and such investment may exceed forty percent (40%) of the paid-in capital of the Company, notwithstanding Article 13 of the Company Act. The Board of Directors (the “Board”) is hereby authorized to make such investments according to the actual needs of the Company.

Article 5 The Company’s head office shall be located in Taipei City. The Board may decide to establish branch institutions in or outside the R.O.C.

Article 6 Any and all public announcements of the Company shall be made in accordance with Article 28 of the Company Act.

Chapter II Shares

Article 7 The Company’s total authorized capital is NT\$3,000,000,000, divided into 300,000,000 shares, each with a par value of NT\$10. The total authorized capital shall be paid in instalments. The Board is hereby authorized to issue the unissued shares in accordance with the actual needs of the Company’s business.

24,000,000 shares of the aforesaid total authorized capital are reserved for employee stock options and the Board is authorized to issue in instalments in accordance with applicable laws and regulations.

Article 8 If the Company would like to issue employee stock options where the exercise price for such options is lower than the closing price of the shares of the Company as of the issuance date, such issuance shall be approved by a resolution passed by two-thirds (2/3) or more of the shareholders at a shareholders’ meeting attended by shareholders who represent more than one-half (1/2) of the total outstanding shares of the Company before such employee stock options can be issued.

If the Company transfers the shares at a price lower than the average price of actual re-purchase of such shares, such transfer shall be approved by a resolution passed by two-thirds (2/3) or more of the shareholders at a shareholders’ meeting attended by shareholders who represent more than one-half (1/2) of the total outstanding shares of the Company before such transfer can be proceeded.

Article 9 If the Company would like to revoke the public offering of the shares of the Company, such proposal shall be submitted to the shareholders' meeting for approval.

Article 10 The Company's share certificates shall bear the shareholders' names and certified by the certification authority approved by the government before such share certificates can be issued.

When issuing shares, the Company may issue shares without printing share certificates for the shares issued, but the Company shall engage a centralized securities depository institution to handle the recording or depository matters. Any issuance of other types of security of the Company shall be subject to the aforementioned restriction.

Article 11 The entries of the shareholders' roster of the Company shall be closed within the period stipulated in Article 165 of the Company Act.

The Company's matters concerning shareholder services shall be administrated in accordance with the Company Act and the "Regulations Governing the Administration of Shareholder Services of Public Companies."

Chapter III Shareholders' Meetings

Article 12 Shareholders' meetings include annual shareholders' meeting and extraordinary shareholders' meetings. The Company shall in each year hold a shareholders' meeting as its annual shareholders' meeting no later than six (6) months after the close of each financial year. An extraordinary shareholders' meeting may be called by the Board as they consider necessary.

The Company's shareholders' meeting can be held by means of visual communication network or other methods promulgated by the central competent authority.

Article 13 A notice to call an annual shareholders' meeting shall be sent to the shareholders thirty (30) days prior to the meeting date; a notice to call an extraordinary shareholders' meeting shall be sent to the shareholders fifteen (15) days prior to the meeting date. Such notice shall state the meeting date, venue and reasons for the meeting. The meeting notice may be given via electronic transmission upon the consent of the receiving party.

Article 14 When a shareholder is unable to attend a shareholders' meeting, he/she or

it may appoint another person his/her/its proxy to attend the meeting. The proxy form, to be printed by the Company, shall state the scope of authorization covered by the proxy and be signed or sealed with the shareholder's chop in accordance with Article 177 of the Company Act.

Except for the aforementioned regulation, all matters concerning proxies shall also be in compliance with the "R.O.C. Regulations Governing the Use of Proxies for Attendance at Shareholder Meetings of Public Companies" issued by the competent authority.

Article 15 Unless there is any regulatory restriction on the voting right of the shares, every shareholder entitled to vote shall have one vote for each share of which he/she/it is the holder.

The voting rights shall be exercised by electronic means and may be exercised by a written ballot if the method for exercising the votes has been described in the notice of the shareholders' meeting.

A shareholder who exercises his/her/its voting power at a shareholders' meeting by way of a written ballot or electronic transmission as set forth in the preceding paragraph shall be deemed to have attended the said shareholders' meeting in person. Matters concerning the written ballot or electronic transmission shall be in compliance with applicable laws and regulations.

Article 16 Unless otherwise provided for in the Company Act or these Articles, a resolution at a shareholders' meeting shall be adopted by a majority vote of the shareholders present, who shall hold more than one-half (1/2) of the total number of shares issued and outstanding.

Article 17 Resolutions adopted at a shareholders' meeting shall be recorded in the minutes of the meeting, which shall be affixed with the signature or seal of the chairperson of the meeting and shall be distributed to all shareholders of the Company within twenty (20) days of the close of the meeting. Such meeting minutes along with the attendance sheet and any proxy statements shall be kept for the term of the existence of the Company.

The distribution of such meeting minutes may be effected by means of a public notice.

The shareholders' meeting shall be conducted in accordance with the "Rules and Procedures of Shareholders' Meetings" of the Company.

Chapter IV Directors and Supervisors

Article 18 The Company shall have a board consisting of five (5) to nine (9) directors, of which at least three (3) independent directors and shall constitute one-fifth (1/5) or more of the total number of directors. The number of directors elected shall be determined in a board meeting. And a candidate nomination mechanism shall be adopted for election of directors in compliance with Article 192-1 of the Company Act. The shareholders shall elect the directors and supervisors from among the candidates. The tenure of office of the directors and the supervisors shall be no more than three (3) years, and they shall be eligible for re-election.

At a shareholders' meeting for election of directors, the number of votes exercisable with respect to one share shall be the same as the number of directors to be elected, and the total number of votes per share may be consolidated for election of one candidate or may be split for election of two or more candidates. A candidate for whom the ballots cast represent a prevailing number of votes shall be deemed a director so elected. Where such mechanism of election is to be amended, the main content of such amendment shall be stated in the shareholders' meeting notice and Article 172 of the Company Act shall be applicable.

The qualifications, shareholding and employment restrictions, election, removal, duties and powers of and other matters relevant to independent directors, shall be in compliance with the applicable regulations.

The company has established an audit Committee in accordance with Article 14-4 of the Securities and Exchange Act. The Audit Committee shall comprise of all the independent directors. The Audit Committee or its members shall be responsible to exercise their powers of the supervisors stipulated in the Company Act, the Securities and Exchange Act and other laws and regulations.

The company may set up other functional committees, whose organizational rules will be implemented after being approved by the Board of Directors.

Article 19 The total shares of registered stock held by the entire body of either directors of the Company shall be in compliance with the "Rules and Review Procedures for Director and Supervisor Share Ownership Ratios at Public Companies."

During the term of the directors, the Company may purchase and maintain

insurance for the benefit of each director or each supervisor against any liability incurred by him/her in his/her capacity as a director or a supervisor.

Article 20 The Board is constituted by the directors. The Chairman of the Board shall be elected from among the directors by a majority vote at a meeting attended by two-thirds (2/3) or more of the directors. The Chairman of the Board shall represent the Company.

Article 21 The Chairman shall be the chairman of Board meetings. If the Chairman of the Board takes leave or is unable to perform his/her duties with cause, his/her proxy shall be determined pursuant to Article 208 of the Company Act. A director may appoint another director as his or her proxy to attend a directors' meeting. The proxy shall accept the appointment of one director only.

Article 22 The notice for a meeting of the Board shall state the reasons for and agenda of the meeting, and shall be sent to each member of the Board seven (7) days prior to the meeting, provided that such period for advance notice may be shortened in the case of an emergency. Such notice may be issued in writing, by email or by facsimile.

The meeting of the Board may be conducted via video conference. A director who attends the meeting of the Board via video conference shall be deemed to have attended such meeting in person.

Article 23 Except as otherwise provided in the Company Act, meetings of the Board shall be called by its Chairman.

Except as otherwise provided in the Company Act or these Articles, resolutions at meetings of the Board shall be adopted by a majority vote at a meeting attended by more than one-half (1/2) of the directors.

Article 24 When the number of vacancies in the Board equals to one third of the total number of directors of the Company have been dismissed, the Board shall call, within sixty (60) days, an extraordinary shareholders' meeting to elect succeeding directors or supervisors to fill the vacancies. The terms of the succeeding directors or supervisors shall be the same as those of the other directors or supervisors.

When an independent director is dismissed for any reason, resulting in a number of directors lower than that required by applicable regulations or these Articles, a by-election for the position of independent director shall be held at the next following shareholders' meeting. When all independent directors have been dismissed, the Company shall convene an

extraordinary shareholders' meeting to hold a by-election within sixty (60) days from the date on which the situation arose.

Article 25 The Board is authorized to determine the compensation of the directors in accordance with their respective involvement in the operations of the Company and contributions to the Company as well as the common compensation standards adopted by domestic and foreign companies in the same industry.

Chapter 5 Managers

Article 26 The Company may have several managers, the appointment, dismissal and compensation of whom shall be handled in accordance with Article 29 of the Company Act and the "Regulations Governing the Appointment and Exercise of Powers by the Remuneration Committee of a Company whose Stock is Listed on the Stock Exchange or Traded Over the Counter."

Chapter VI Accounts

Article 27 At the close of each financial year, the Board shall prepare the following reports for the regular shareholders' meeting according to law for its ratification:

- (1) a report on operations;
- (2) a financial reports; and
- (3) a proposal for distribution of profits or covering losses.

Article 28 When there are earnings in a given fiscal year, after offsetting accumulated losses, it shall allocate one (1) to ten (10) percent of the remaining amount as employees' compensation and no more than two (2) percent as directors' compensation. Of the amount allocated as employees' compensation, five (5) to ten (10) percent shall be designated for distribution to grassroots-level employees. The employees' compensation may be distributed in cash or in the form of shares of the Company. The directors' compensation shall be distributed in cash only. The distribution of the employees' compensation and directors' compensation shall be submitted to the Board for its approval, and be reported to the shareholders' meeting.

Whatever the company exerts on rewarding employees affiliated with the company, such as offering employees' compensation, issuing employee stock option warrants, issuing new shares to these employees with their rights reserved, issuing restricted shares, and transferring the repurchased

shares to employees, the target may include employees of controlled companies or subsidiaries that meet the requirements determined by the Board of Directors.

When there is any profit for distribution in a given financial year, the Company shall first pay all applicable taxes and offset losses from previous years, and then set aside ten (10) percent of the remaining profits of the Company from the relevant financial year as a legal reserve; where such legal reserve is equal in amount to the authorized capital of the Company, the Company may not set aside such legal reserve. The Company may set aside a special reserve from the remaining profit. When distributing surplus earning in the form of new shares to be issued, the Board may submit the distribution proposal to set aside the remaining profit for the relevant financial year and previous financial years for the approval of the shareholders' meeting.

The profit policy of the Company should be consistent with the current and future development of the Company, the investment environment, needs for funding and competition domestically and abroad, and the protection of shareholders. The Company may distribute bonuses to shareholders from the remaining profit of the relevant financial year. The bonus to shareholders may be distributed in cash or stock dividends, and the dividends (including cash or in the form of shares) shall be no less than ten (10) percent of the after tax earnings. The cash dividends shall comprise no less than ten (10) percent of the aggregate of the cash and stock dividends declared in such year.

Distributing dividends, bonuses, the legal reserve and the capital reserve in whole or in part may be paid in cash after a resolution has been adopted by a majority vote at a meeting of the board of directors attended by two-thirds (2/3) of the total number of directors; and in addition thereto a report of such distribution shall be submitted to the shareholders' meeting.

Chapter VII Supplementary Provisions

- Article 29 Matters not covered by the Articles of Incorporation shall be dealt with according to the provisions of the Company Act and applicable laws.
- Article 30 The Articles of Incorporation were agreed upon and signed on January 10, 2013.

The First Amendment was made on July 4, 2014.

The Second Amendment was made on February 17, 2015.

The Third Amendment was made on August 3, 2015.

The Fourth Amendment was made on June 29, 2016.

The Fifth Amendment was made on June 26, 2018.

The Sixth Amendment was made on June 28, 2019.

The Seventh Amendment was made on June 29, 2020.

The Eighth Amendment was made on June 29, 2022.

The Ninth Amendment was made on May 29, 2025.

Foresee Pharmaceuticals Co., Ltd.

Chairman: Benjamin Chien

【Appendix 2】

Rules and Procedures of Shareholders' Meetings

Foresee Pharmaceuticals Co., Ltd.
(the “Company”)

Rules and Procedures of Shareholders’ Meetings

Article 1 Unless being contradicts to relevant laws and regulations, Shareholders' Meetings of the Company (the "Meeting") shall be conducted in accordance with these Rules and Procedures of Shareholders’ Meetings (the “Procedures”).

Article 2 Shareholders attending the Meeting shall present their attendance cards for the purpose of signing in. The number of shares represented by shareholders attending the Meeting shall be calculated in accordance with the attendance cards, and the shares checked in on the virtual Meeting platform, submitted by the shareholders plus the number of shares whose voting rights are exercised by correspondence or electronically.

Article 3 The Meeting shall be held at the head office of the Company or at any other appropriate place that is convenient for the shareholders to attend. Full consideration shall be given to the opinions of the independent directors of the Company with respect to the place and time of the meeting. The time to start the Meeting shall not be earlier than 9:00 a.m. or later than 3:00 p.m.

The restrictions on the place of the meeting shall not apply when the Company convenes a virtual-only shareholders meeting.

When the Company convenes a virtual-only Meeting, both the chair and secretary shall be in the same location, and the chair shall declare the address of their location when the Meeting is called to order.

Article 4 The Company may appoint designated counsels, CPAs or other related persons to attend the Meeting. Persons handling affairs of the Meeting shall wear identification cards or badges.

Article 5 The Company, beginning from the time it accepts shareholder attendance registrations, shall make an uninterrupted audio and video recording of the registration procedure, the proceedings of the Meeting, and the voting and vote counting procedures, and these tapes shall be preserved for at least one year.

If, however, a shareholder files a lawsuit pursuant to Article 189 of the Company Act, the recording shall be retained until the conclusion of the litigation.

Where a Meeting is held online, the Company shall keep records of shareholder registration, sign-in, check-in, questions raised, votes cast, and results of votes counted by the Company, and continuously audio and video record, without interruption, the proceedings of the virtual meeting from beginning to end.

The information and audio and video recording in the preceding paragraph shall be properly kept by the Company during the entirety of its existence, and copies of the audio and video recording shall be provided to and kept by the party appointed to handle matters of the virtual Meeting.

Article 6 The chairman of the board of directors of the Company shall be the chairperson presiding at the Meeting in the event that the Meeting is convened by the board of directors. If the chairman of the Company is on leave or for any reason unable to exercise the powers of the chairman, one of the directors shall serve as the chairperson of the Meeting in accordance with Article 208 of the Company Law of the Republic of China.

When a director of the Company serves as the chairperson of the Meeting on behalf of the chairman of the Company, as referred to in the preceding paragraph, that director shall be one who has held that position for six months or more and who understands the financial and business conditions of the Company. The same shall be true for a representative of a juristic person director that serves as the chairperson of the Meeting.

It is advisable that a Meeting convened by the board of directors of the Company be chaired by the chairman of the Company in person and attended by a majority of the directors and at least one member of each functional committee on behalf of the committee. The attendance shall be recorded in minutes of the Meeting.

If the Meeting is convened by any other person entitled to convene the Meeting other than the board of directors of the Company, such person shall be the chairperson to preside at the Meeting. However, that if there are two or more persons having the convening right, the chairperson of the Meeting shall be elected from among such persons.

Changes to how the Company convenes its the Meeting shall be resolved by the board of directors, and shall be made no later than mailing of the Meeting notice.

Article 7 The chairperson of the Meeting shall call the Meeting to order at the time scheduled for the Meeting, and announced relevant information such as the number of non-voting rights and the number of shares present. If the number of shares represented by the shareholders present at the Meeting does not yet constitute a quorum at the time scheduled for the Meeting, the chairperson may postpone the time for the Meeting. The postponements shall be limited to two times at the most and Meeting shall not be postponed for longer than one hour in the aggregate. If the quorum is not met after two postponements and the attending shareholders still represent less than one third of the total number of issued shares, the chair shall declare the Meeting adjourned. In the event of a virtual Meeting, the Company shall also declare the Meeting adjourned at the virtual Meeting platform. If after two postponements a quorum has not yet been reached but the shareholders present at the Meeting represent more than one-third of the total outstanding shares, tentative resolutions may be made in accordance with Section 1 of Article 175 of the Company Law of the Republic of China. All shareholders shall be notified of the tentative resolution and another Meeting shall be convened within one month. In the event of a virtual Meeting, shareholders intending to attend the Meeting online shall re-register to the Company in accordance with Article 10.

If during the Meeting the number of outstanding shares represented by the shareholders present becomes sufficient to constitute a quorum, the chairperson of the Meeting may submit the tentative resolutions to the Meeting for approval in

accordance with Article 174 of the Company Law of the Republic of China.

Article 8 The agenda of the Meeting shall be set by the board of directors of the Company if the Meeting is convened by the board of directors. Votes shall be cast on each separate proposal in the agenda (including extraordinary motions and amendments to the original proposals set out in the agenda). Unless otherwise resolved at the Meeting, the Meeting shall proceed in accordance with the agenda.

The above provision applies mutatis mutandis to cases where the Meeting is convened by any person, other than the board of directors, entitled to convene such Meeting. If the meeting venue is no longer available for continued use and not all of the items (including motions) on the meeting agenda have been addressed, the Meeting may adopt a resolution to resume the meeting at another venue.

Unless otherwise resolved at the Meeting, the chairperson of the Meeting cannot announce adjournment of the Meeting before all the discussion items (including special motions) listed in the agenda are resolved.

The shareholders cannot designate any other person as chairperson and continue the Meeting in the same or other place after the Meeting is adjourned. However, in the event that the chairperson of the Meeting adjourns the Meeting in violation of these Procedures, the shareholders may designate, by a majority of votes represented by the shareholders attending the Meeting, one person as the chairperson of the Meeting to continue the Meeting.

Article 9 Shareholders attending the Meeting shall have the obligation to obey these Procedures, to comply with the resolutions and maintain order at the Meeting place.

Article 10 The Company shall specify in notice of the Meeting the time during which attendance registrations for shareholders, solicitors and proxies (collectively “shareholders”) will be accepted, the place to register for attendance, and other matters for attention.

The time during which shareholder attendance registrations will be accepted, as stated in the preceding paragraph, shall be at least 30 minutes prior to the time the Meeting commences. The place at which attendance registrations are accepted shall be clearly marked and with a sufficient number of suitable personnel assigned to handle the registrations. For virtual Meetings, shareholders may begin to register on the virtual Meeting platform 30 minutes before the Meeting starts. Shareholders completing registration will be deemed as attend the Meeting in person.

Shareholders shall attend the Meeting based on attendance cards, sign-in cards, or other certificates of attendance. The Company may not arbitrarily add requirements for other documents beyond those showing eligibility to attend presented by shareholders. Solicitors soliciting proxy forms shall also bring identification documents for verification.

The Company shall furnish the attending shareholders with an attendance book to sign, or attending shareholders may hand in a sign-in card in lieu of signing in. The Company shall furnish attending shareholders with the meeting agenda book, annual report, attendance card, speech note, voting ballots, and other meeting materials.

Where there is an election of directors of the Company, pre-printed ballots shall also be furnished.

When the government or a juristic person is a shareholder, it may be represented by more than one representative at the Meeting.

In the event of a virtual Meeting, shareholders wishing to attend the Meeting online shall register with the Company two days before the meeting date.

In the event of a virtual Meeting, the Company shall upload the Meeting agenda book, annual report and other meeting materials to the virtual meeting platform at least 30 minutes before the Meeting starts, and keep this information disclosed until the end of the Meeting.

Article 11 When a shareholder presenting at the Meeting wishes to speak, a speech note should be filled out with a summary of the speech, the shareholder's account number (or the number of the shareholder's attendance card) and the name of the shareholder. The sequence of speeches by shareholders should be decided by the chairperson of the Meeting.

Unless otherwise permitted by the chairperson of the Meeting, each shareholder shall not, for each discussion item, speak more than two times (each time not exceeding 5 minutes). In the event that the speech of any shareholder violates the above provision or exceeds the scope of the discussion item, the chairperson of the Meeting may stop the speech of such shareholder.

If any shareholder presenting at the Meeting submits a speech note but does not speak, no speech should be deemed to have been made by such shareholder. In the event that the contents of the speech of a shareholder are inconsistent with the contents of the speech note, the contents of the actual speech shall prevail.

Unless otherwise permitted by the chairperson of the Meeting and the shareholder who is speaking, no shareholder shall interrupt the speeches of the other shareholders; otherwise the chairman shall stop such interruption.

If a shareholder which is a juristic person designates two or more representatives to attend the Meeting, only one representative can speak for each discussion item.

After the speech of a shareholder, the chairperson of the Meeting may respond himself/herself or appoint an appropriate person to respond.

Where a virtual Meeting is convened, shareholders attending the virtual Meeting online may raise questions in writing at the virtual meeting platform from the chair declaring the Meeting open until the chair declaring the Meeting adjourned. No more than two questions for the same proposal may be raised. Each question shall contain no more than 200 words. The regulations in paragraphs 1 to 5 do not apply.

Article 12 The chairperson of the Meeting may announce the end of the discussion of any resolution and proceed to voting if the chairperson deems it appropriate.

Article 13 Vote monitors and vote counters during a vote shall be appointed by the chairperson

of the Meeting. The vote monitors shall be shareholder of the Company. Vote counting for proposals or elections of the Meeting shall be conducted in public at the place of the Meeting. The result of voting shall be promptly announced at the Meeting and placed on record.

When the Company convenes a virtual Meeting, after the chair declares the Meeting open, shareholders attending the Meeting online shall cast votes on proposals and elections on the virtual meeting platform before the chair announces the voting session ends or will be deemed abstained from voting.

In the event of a virtual Meeting, votes shall be counted at once after the chair announces the voting session ends, and results of votes and elections shall be announced immediately.

When the Company convenes a hybrid Meeting, if shareholders who have registered to attend the Meeting online in accordance with Article 10 decide to attend the physical Meeting in person, they shall revoke their registration two days before the Meeting in the same manner as they registered. If their registration is not revoked within the time limit, they may only attend the Meeting online.

When shareholders exercise voting rights by correspondence or electronic means, unless they have withdrawn the declaration of intent and attended the Meeting online, except for extraordinary motions, they will not exercise voting rights on the original proposals or make any amendments to the original proposals or exercise voting rights on amendments to the original proposal.

Article 14 Except where otherwise specified in the Company Law of the Republic of China or the articles of incorporation of the Company, a resolution shall be adopted by a majority of the votes represented by the shareholders present at the Meeting. At the time of a vote, for each proposal, the chairperson of the Meeting or a person designated by the chairperson shall first announce the total number of voting rights represented by the attending shareholders, followed by a poll of the shareholders. After the conclusion of the meeting, on the same day it is held, the results for each proposal, based on the numbers of votes for and against and the number of abstentions, enter into the Market Observation Post System (“MOPS”).

In the event of a virtual Meeting, the Company shall disclose real-time results of votes and election immediately after the end of the voting session on the virtual meeting platform according to the regulations, and this disclosure shall continue at least 15 minutes after the chair has announced the Meeting adjourned.

Article 15 During the Meeting, the chairperson of the Meeting may, at his discretion, set time for intermission. In case of an incident of force majeure, the chairperson may decide to temporarily suspend the Meeting and announce, depending on the situation, when the Meeting will resume. Alternatively, by resolution of the shareholders present at the Meeting, to resume the Meeting within five days without further notice or public announcement.

Article 16 If there is amendment to or a substitution for a discussion item, the chairperson of the Meeting shall decide the sequence of voting for such discussion item, the amendment, or the substitute discussion item. If any one of them has been adopted,

the others shall be deemed rejected and no further voting is necessary.

Article 17 The chairperson of the Meeting may direct the disciplinary officers or the security guard to assist in keeping order in the Meeting place. Such disciplinary officers or security guards shall wear badges marked "Disciplinary Officers" for identification purpose.

If public address equipment is set up in the Meeting place, if a shareholder attempts to speak through any device other than the equipment set up by the Company, the chairperson of the Meeting may prevent the shareholder from so doing.

When a shareholder violates these Procedures and defies the correction of the chairperson of the Meeting, obstructing the proceedings and refusing to heed calls to stop, the chairman may direct the disciplinary officers or security guards to escort the shareholder from the meeting.

Article 18 On the day of the Meeting, the Company shall compile in the prescribed format a statistical statement of the number of shares obtained by solicitors through solicitation, the number of shares represented by proxies and the number of shares represented by shareholders attending the meeting by correspondence or electronic means, and shall make an express disclosure of the same at the place of the Meeting. In the event a virtual Meeting, the Company shall upload the above meeting materials to the virtual meeting platform at least 30 minutes before the Meeting starts, and keep this information disclosed until the end of the Meeting.

During the Company's virtual Meeting, when the Meeting is called to order, the total number of shares represented at the Meeting shall be disclosed on the virtual meeting platform. The same shall apply whenever the total number of shares represented at the Meeting and a new tally of votes are released during the Meeting.

Where matters put to a resolution at the Meeting constitute material information under applicable laws or regulations or under regulations promulgated by Taiwan Stock Exchange Corporation or Taipei Exchange, the Company shall upload the content of such resolution to the MOPS within the prescribed time period.

Article 19 In the event of a virtual Meeting, if the virtual meeting platform or participation in the virtual Meeting is obstructed due to natural disasters, accidents or other force majeure events before the chair has announced the Meeting adjourned, and the obstruction continues for more than 30 minutes, the Meeting shall be postponed to or resumed on another date within five days, in which case Article 182 of the Company Act shall not apply.

For a meeting to be postponed or resumed as described in the preceding paragraph, shareholders who have not registered to participate in the affected Meeting online shall not attend the postponed or resumed session.

For a meeting to be postponed or resumed under the first paragraph, the number of shares represented by, and voting rights and election rights exercised by the shareholders who have registered to participate in the affected Meeting and have successfully signed in the Meeting, but do not attend the postpone or resumed session, at the affected Meeting, shall be counted towards the total number of shares,

number of voting rights and number of election rights represented at the postponed or resumed session.

During a postponed or resumed session of a Meeting held under the first paragraph, no further discussion or resolution is required for proposals for which votes have been cast and counted and results have been announced, or list of elected directors.

When the Company convenes a hybrid Meeting, and the virtual Meeting cannot continue as described in first paragraph, if the total number of shares represented at the Meeting, after deducting those represented by shareholders attending the virtual Meeting online, still meets the minimum legal requirement for a Meeting, then the Meeting shall continue, and not postponement or resumption thereof under the first paragraph is required.

Under the circumstances where a Meeting should continue as in the preceding paragraph, the shares represented by shareholders attending the virtual Meeting online shall be counted towards the total number of shares represented by shareholders present at the Meeting, provided these shareholders shall be deemed abstaining from voting on all proposals on meeting agenda of that Meeting.

When postponing or resuming a Meeting according to the first paragraph, the Company shall handle the preparatory work based on the date of the original Meeting in accordance with the requirements listed under Article 44-20, paragraph 7 of the Regulations Governing the Administration of Shareholder Services of Public Companies.

For dates or period set forth under Article 12, second half, and Article 13, paragraph 3 of Regulations Governing the Use of Proxies for Attendance at Shareholder Meetings of Public Companies, and Article 44-5, paragraph 2, Article 44-15, and Article 44-17, paragraph 1 of the Regulations Governing the Administration of Shareholder Services of Public Companies, the Company shall handle the matter based on the date of the Meeting that is postponed or resumed under the first paragraph.

Article 20 These Procedures shall be effective from the date it is approved by the Meeting. The same applies to revisions to these Procedures.
The Rules and Procedures of Shareholders' Meetings were agreed upon and signed on June 19, 2015.
The First Amendment was made on June 29, 2021.
The Second Amendment was made on June 29, 2022.

【Appendix 3】

Shareholdings of All Directors

Record Date: March 23, 2026

Title	Name	Shareholder Represented	Shares
Chairman	Ben Chien	Foresee Pharmaceuticals, Inc.	23,710,357
Director	Vincent Yen		
Director	Yisheng Lee		
Director	George Lee		49,187
Director	Jeff Wang		13,000
Independent Director	Frank Lee		112,589
Independent Director	Fu-Shiow Yin		0
Independent Director	Hank Lai		0
Independent Director	Ben Liu		0
Total Shares (excluding Independent Directors):			23,772,544

As of the Record Date, the total issued and outstanding common shares of the Company are 157,540,541 shares.